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ABSTRACT
ROLE OF MICROGLIAL α7 NICOTINIC ACETYLCHOLINE
RECEPTOR POSITIVE ALLOSTERIC MODULATOR IN NEUROINFLAMMATORY
PAIN MODELS IN MICE
MUZAFFAR ABBAS
2016
Neuroinflammatory pain affects about 1.5% of the United States population. Around

20-40% patients having neurological disorders are affected with neuroinflammatory pain.
As a part of the limbic system, hippocampus is known to play a critical role in pain
perception and processing, and is densely populated with microglial cells and α7 nicotinic
acetylcholine receptors (nAChRs). Given the role of microglial α7 nAChRs in
neuroinflammation, the α7 nAChRs have emerged as potential target for
neuroinflammatory pain treatment. We hypothesized that microglial α7 nAChRs positive
allosteric modulation in the hippocampus will decrease neuroinflammatory pain at
behavioral, cellular, biochemical, and molecular level. The primary objective of current
study was to examine the role of an α7 nAChR positive allosteric modulator (PAM),
TQS, in neuroinflammatory pain and to determine biochemical, cellular, and molecular
mechanisms associated with neuroinflammatory pain in the hippocampus using mouse
models.
We demonstrated that TQS reduced neuroinflammatory pain-like symptoms,
including tactile allodynia and thermal hyperalgesia in mice. Methyllcaconitine, an α7
nAChR antagonist, reversed antiallodynic and antihyperalgesic effects of TQS suggesting
the involvement of α7 nAChR. The TQS decreased the expression of ionized calcium-

xvii
binding adapter molecule 1 and cluster of differentiation 11b, microglial activation
markers, in the hippocampus. We determined that TQS reduced inhibitor of kappa B, a
downstream mediator that decreases due to nuclear factor-κB (NF-κB) inactivation, and
p-NF-κB p65 expression in the hippocampus. In addition, TQS reduced the expression of
tumor necrosis factor (TNF) and increased the level of norepinephrine in the
hippocampus. We determined that TQS decreased the expression of brain-derived
neurotrophic factor (BDNF). Similarly, we determined that TQS reduced the activation of
Na-K-Cl cotransporter 1 and increased K-Cl co-transporter 2 expression.
Taken together, our results indicated that TQS decreased microglial TNF and
BDNF expression and associated signaling in neuroinflammatory pain involving α7
nAChR and microglial activation. Our findings provided strong and novel evidence that
microglial α7 nAChR positive allostetric modulation-mediated signaling regulate
behavioral, cellular, biochemical, and molecular mechanisms underlying
neuroinflammatory pain. Therefore, targeting microglial α7 nAChR positive allosteric
modulation in the hippocampus might be a novel strategy for the treatment of
neuroinflammatory pain.
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1
OVERVIEW
Neuroinflammatory pain is a chronic neurological disorder affecting about 1.5%
of the United States population and is associated with microglial activation (Carter and
Galer, 2001; Yoon et al., 2012). Various pharmacological ligands that mediate microglial
activation cause neuroinflammatory pain development. For example lipopolysaccharide
(LPS) causes microglial activation and induces neuroinflammatory pain-like symptoms
(Yoon et al., 2012). Fractalkine, the microglial activator, results in development of
behavioral signs of neuroinflammatory pain, including tactile allodynia, and thermal
hyperalgesia (Milligan et al., 2004). Furthermore, microglial activation modulators,
including fluorocitrate (Meller et al., 1994; Watkins et al., 2007), minocycline (Ledeboer
et al., 2005; Mika, 2008; Yoon et al., 2012), ibudilast (Ledeboer et al., 2007), and
propentofylline (Sweitzer and De Leo, 2011) are effective in neuroinflammatory pain.
As a part of the limbic system, hippocampus has been known for pain processing
and perception (Khanna and Sinclair, 1989; Martuscello et al., 2012). Studies have shown
that cholinergic nicotinic pathway exists in the hippocampus which modulates microglial
activation involving α7 nicotinic acetylcholine receptors (Pavlov and Tracey, 2006;
Shytle et al., 2004). Therefore, hippocampal α7 nicotinic acetylcholine receptors have
emerged as novel therapeutic targets for neuroinflammatory pain. The α7 nicotinic
acetylcholine receptors are metabotropic and are extensively distributed on microglial
cells in the hippocampus. The role of α7 nicotinic acetylcholine receptors-mediated
signaling in neuroinflammatory pain is less understood at behavioral, cellular,
biochemical, and molecular level. Since α7 nicotinic acetylcholine receptors undergo
rapid desensitization, therefore, targeting α7 nicotinic acetylcholine receptors through
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positive allosteric modulation and associated mechanisms offers an alternative approach
to treat neuroinflammatory pain.
Given the significant association of neuroinflammatory pain and microglial
activation involving α7 nicotinic acetylcholine receptors positive allosteric modulation,
we hypothesized that TQS, an α7 nicotinic acetylcholine receptors positive allosteric
modulator, will play a critical role in regulating behavioral, cellular, biochemical, and
molecular mechanisms underlying neuroinflammatory pain. Therefore, the primary goal
of this dissertation was to examine the functional role of microglial α7 nicotinic
acetylcholine receptors positive allosteric modulator in the hippocampus in
neuroinflammatory pain using behavioral methods, including tactile allodynia and
thermal hyperalgesia and cellular, biochemical and molecular techniques, including
immnunofluorescence assay, diaminobenzidine immunohistochemistry, enzyme-linked
immunosorbent assay, norepinephrine assay, Western blot analysis, and quantitative realtime polymerase chain reaction in mice.
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Chapter 1: General Introduction
1.1. Neuroinflammatory pain
Neuroinflammatory pain is a chronic neurological disorder characterized by
hyperalgesia (increased responsiveness to painful stimulus) and allodynia (painful
response to normally innocuous stimulus) (Cao and Zhang, 2008; Ji and Wen, 2006; Xu
and Yaksh, 2011). The prevalence of neuroinflammatory pain is 1.5% in the United
States (Carter and Galer, 2001). Moreover, about 20-40% patients having neurological
disorders are affected with neuroinflammatory pain (Borsook, 2012). Previous study
showed that neuroinflammatory pain arises due to tissue damage or inflammation (Cao
and Zhang, 2008). This exaggerated pain state occurs due to peripheral sensitization
and/or central sensitization (Ji and Woolf, 2001).
The neuroinflammatory pain has been shown to be associated with various
neurological disorders, including Parkinson’s disease, Huntington’s disease, Alzheimer’s
disease, multiple sclerosis, spinal cord injury, diabetic neuropathy, complex regional pain
syndrome, post-herpetic neuralgia, and traumatic brain injury (Borsook, 2012). The
neuroinflammatory pain shares some common characteristics with neuropathic pain.
These include involvement of activated microglia (Scholz and Woolf, 2007; Svensson et
al., 2003; Watkins et al., 2001), nuclear factor κB (NF-κB), proinflammatory cytokines,
including tumor necrosis factor (TNF) (Junger and Sorkin, 2000; Schafers et al., 2003;
Sommer et al., 2001; Taylor and Feldmann, 2009), norepinephrine (NE) (Covey et al.,
2000), brain-derived neurotrophic factor (BDNF), potassium-chloride co-transporter 2
(KCC2) (Nomura et al., 2006), and sodium-potassium-chloride co-transporter 1
(NKCC1) (Galan and Cervero, 2005; Pitcher and Cervero, 2010; Price et al., 2009). Thus,
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these mediators/transporters may need to be inhibited for the blockade of
neuroinflammatory and neuropathic pain conditions.
Various pharmacologicial agents, including anticonvulsants such as gabapentin,
and pregabalin, tricyclic antidepressants, including amitriptyline, desipramine, and
nortriptyline, selective serotonin norepinephrine reuptake inhibitors such as duloxetine,
and venlafaxine, and topical lidocaine have been used as first-line medications for
neuroinflammatory pain (Dworkin et al., 2007). Opioids, including tramadol, morphine,
fentanyl, and oxycodone have been used as second-line medications that are suitable for
first-line use in certain circumstances in neuroinflammatory pain (Dworkin et al., 2007).
Several other medications have shown efficacy for the treatment of
neuroinflammatory pain and are also currently used as third line medications. These
include antiepileptic medications (e.g., carbamazepine, lamotrigine, oxcarbazepine,
topiramate, levetiracetam, zonisamide tiagabine, and valproic acid), antidepressants (e.g.,
citalopram, and bupropion), mexiletine, and dextromethorphan. Despite the availability
of these different treatment options, effective management of neuroinflammatory pain
remains limited due to multiple therapeutic challenges. For example, available
medications for neuroinflammatory pain have significant limitations, including limited
efficacy, and adverse effects. Thus, there is a need to develop new drugs and explore
new brain targets, including hippocampus for the treatment of neuroinflammatory pain.
1.1.1. Hippocampus and neuroinflammatory pain
Hippocampus, the part of limbic system and classically known for memory and
learning function, has been known for pain perception (Martuscello et al., 2012; Mutso et
al., 2012). It has been less systematically studied with regard to neuroinflammatory pain.
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Moreover, it is critically involved in altering mood states (Khanna and Sinclair, 1989).
This region is known to process both indirect and direct pain inputs. The indirect inputs
innervate the hippocampus involving parabrachial and spinothalamic ascending pathways
from the periphery (Duric and McCarson, 2006), while hippocampus receives direct
inputs from spinal cord (Cliffer et al., 1988; Dutar et al., 1985; Khanna and Sinclair,
1989). Furthermore, hippocampus is known to interact with other brain areas involved in
pain processing, including thalamus (Apkarian et al., 2004), prefrontal cortex (Baliki et
al., 2006; Baliki et al., 2008; Metz et al., 2009), anterior cingulate cortex (Li et al., 2010),
amygdale (Han and Neugebauer, 2005; Ji et al., 2010), and brain stem (Duric and
McCarson, 2007; Suzuki et al., 2002) (Figure 1).
Previous studies have indicated hippocampal abnormalities in animal models of
pain, including abnormal proinflammatory cytokine production (Al-Amin et al., 2011; del
Rey et al., 2011), deficits in long-term potentiation (Kodama et al., 2007), impaired
neurogenesis (Terada et al., 2008), and decreased hippocampal volume (Zimmerman et
al., 2009). Previous studies have shown that upon activation, microglia release
proinflammatory cytokines, including TNF which increases synaptic transmission in the
hippocampus (Beattie et al., 2002; Viviani et al., 2003; Woolf and Salter, 2000). This
then results in hypersensitivity of neurons in dorsal horn of spinal cord and causes
increased pain sensation (DeLeo et al., 2004; Marchand et al., 2005; Sommer and Kress,
2004). The influence of neuroimmune system and associated mechanisms on the
expression and release of neuroglial pain mediators within the hippocampus is not
known. Therefore, blocking these mediators in the hippocampus might be better
therapeutic strategy for neuroinflammatory pain.
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Figure 1: Schematic diagram showing the role of hippocampus (HP) in pain. The HP
receives pain inputs from thalamus (TH) through spinothalamic tract (STT). The HP also
interact with other areas involved in pan perception/transmission, including anterior
cingulated cortex (ACC), prefrontal cortex (PFC), brain stem (BS), and spinal cord (SC).
Amygdala (Amy) receives pain inputs from parabrachial tract (PBT) and interacts HP,
modulating pain processing and perception. Modified and adopted from Ji et al. (2010) J
Neurosci 30:5451-5464; Li et al. (2010) Science 330:1400-1404; Mutso et al. (2012) J
Neurosci 32:5747-5756.
1.1.2. Neuroglial cells
Neuroglial cells refer to diverse group of specialized cells that are found both in
the peripheral nervous system (perineural glia, satellite glia, and Schwann cells) and
central nervous system (CNS) (microglia cells, astrocytes, and oligodendrocytes)
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(Kriegstein and Alvarez-Buylla, 2009). These cells constitute about 70% of total cell
population in the CNS. Neuroglial cells are non-conducting cells that provide structural
support to brain. They help in development, maintenance, repair, supplying biosynthetic
products and nutrients to neurons, damaging and removing neurons those undergo death,
and finally help in regulating the neuronal microenvironment. Neuroglial cells are further
divided into microglial cells which comprise about 5-10% population of glial cells and
macroglia which include astrocytes and oligodendrocytes (Moalem and Tracey, 2006).
Among neuroglial cells, microglial cells play a critical role in painful behavior
(Alfonso Romero-Sandoval and Sweitzer, 2015). Microglial cells are known as immune
system’s ambassadors in the CNS and are closely related to macrophages. They fight
against infections, and release various mediators that may hypersensitize neurons and
play very important role in the mediation of pain (Cao and Zhang, 2008). Astrocytes
have been shown to play a critical in pain pathology. The relative contribution of
astrocytes versus microglial cells in lipopolysaccharide (LPS)-induced
neuroinflammatory pain is not well defined (Guo and Schluesener, 2006; Lee et al.,
2010).
1.1.3. Microglial cells and neuroinflammatory pain
Microglial cells, the macrophage-like cells in the CNS, maintain immune
surveillance. It is reported that microglial activation happens within minutes (min)
(Colton and Wilcock, 2010) but it can be long lasting (Morioka et al., 1991). Microglial
cells are either protective or detrimental to neurons depending upon how they become
activated. For example, pathology arises when microglial cells are fully activated and
their repair efforts fail (Aamodt, 2007). These cells work as a sensors for threats and

8
considered as first cells that respond to injury (Graeber, 2010; Graeber and Streit, 2010).
Microglial cells are known to become activated in neuroinflammatory pain conditions
involving NF-κB activation (Alfonso Romero-Sandoval and Sweitzer, 2015; Loram et al.,
2010).
Various microglial modulators have shown promising results in preclinical
models of pain in the spinal cord. These include fluorocitrate (Meller et al., 1994;
Watkins et al., 2007), minocycline (Ledeboer et al., 2005; Mika et al., 2013; Yoon et al.,
2012), ibudilast (Ledeboer et al., 2007), and propentofylline (Sweitzer and De Leo,
2011). Fluorocitrate is a microglial metabolic inhibitor. It was the first microglial
modulator that was indicated to reduce neuroinflammatory pain (Milligan et al., 2003).
Minocycline is tetracycline antibiotic that is shown to inhibit pain behavior by inhibiting
microglial activation in different neuroinflammatory pain and neuropathic pain models
(Bastos et al., 2007; Cho et al., 2006; Hains and Waxman, 2006; Pabreja et al., 2011).
Ibudilast, a phosphodieastrase inhibitor, also inhibits microglial activation and reduces
neuroinflammatory pain-like symptoms in different preclinical models (Ellis et al., 2014;
Ledeboer et al., 2006). Propentofylline, a methylxanthine derivative and
phosphodiestrase inhibitor, also decreases pain-related behavior in animal models by
inhibiting microglial activation (Sweitzer et al., 2006; Sweitzer et al., 2001). These
findings formed a sound foundation that microglial cells play a critical role in various
pain modalities and microglial modulators produce promising results against
neuroinflammatory pain.
The term microgliosis (microglial activation) refers to changes in cell
morphology, and enhanced expression of microglial mediators, including cluster of
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differentiation (CD)11b and ionized calcium-binding adapter molecule 1 (Iba-1) (Alfonso
Romero-Sandoval and Sweitzer, 2015; Cao and Zhang, 2008; Ehlers, 2000; Kettenmann
et al., 2011; Kreutzberg, 1996; Nakajima and Kohsaka, 2001).
As indicated earlier, microglial activation is characterized by morphological
changes. Previous studies have shown that microglial cells adopt resting phenotype in
inactivated state but undergo rapid activation in response to acute insults. This results in
change in their morphological shape characterized by hypertrophy, retracted processes,
and amoeboid morphology under strongly pathological conditions (Chen et al., 2012;
Tsuda et al., 2005; Watkins and Maier, 2003; Zielasek and Hartung, 1996).
Bacterial LPS is a well-known toll-like receptor 4 (TLR4) agonist, used to induce
microglial activation involving morphological changes (Chen et al., 2012). Although
TLR4 antagonists have shown promising results to modulate neuroinflammatory painlike symptoms (Bettoni et al., 2008), targeting TLR4 for neuroinflammatory pain might
be risky due to cancer or infectious disease development (Alfonso Romero-Sandoval and
Sweitzer, 2015).
The Iba-1 is 17 Kilodaltons (KDa) protein and is restricted to microglia (Imai et
al., 1996). Very little is known about the functions of Iba-1. This protein is known to take
part in reorganizing the cytoskeleton within the microglia. Studies have shown that
expression of Iba-I is up-regulated when microglial cells become activated (Mori et al.,
2000; v Eitzen et al., 1998).Thus increased expression of Iba-I implicates microglial
activation. Like Iba-1, CD11b is also microglail activation marker. It is 127 kDa protein
and is found be unregulated in neuroinflammatory pain in animal models (Loram et al.,
2010). Previous studies showed that CD11b and Iba-1 are not only the mediators up-
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regulated during microglial activation but also other mediators, including NF-κB is
increased (Loram et al., 2010; Yoon et al., 2012). Taken together, these findings indicate
that microglial morphological changes, and up-regulation of Iba-1 and CD11b can be
used as markers for microglial activation. Therefore, reducing microglial activation and
associated mediators, including NF-κB might be better therapeutic strategy for
neuroinflammatory pain treatment.
1.1.4. The NF-κB and neuroinflammatory pain
Until recently, the neuronal dysfunction has been considered to play a critical role
in the development of pain hypersensitivity (Watkins et al., 2001; Zhuo et al., 2011).
However, recent evidence indicates that microglial cells involving active NF-κB, a
transcription factor, are important regulators in the development and maintenance of
neuroinflammatory pain (Loram et al., 2010; Watkins et al., 2001; Zhuo et al., 2011).
Therefore, NF- κB has emerged as potential target of importance due to its dysregulation
in neuroinflammatory pain (Loram et al., 2010).
Previous studies indicate that in resting cells, NF-κB remains in inactivated form
by binding to inhibitor of κB (IκB) within the cytoplasm (DiDonato et al., 1996).
However, upon appropriate stimulation, such as during inflammation, IκB becomes
phosphorylated and is exposed to proteolytic degradation (Gao et al., 2000). The
degradation of IκB unmasks NF-κB from inactive to active state. The active NF-κB is
then translocated to nucleus and positively regulates the transcription of various pain
mediating genes, including IκB (Li and Verma, 2002; Pahl, 1999; Sun et al., 1993) as a
part of autoregulatory feedback loop. Therefore, enhanced expression of IκB mRNA
parallels increased NF-κB activity and is used as an index for increased NF-κB activation
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in neuroinflammatory pain (Ledeboer et al., 2005; Loram et al., 2010; Yoshikawa et al.,
2006). Moreover, NF-κB is critically involved in the expression of BDNF and
proinflammatory cytokines, including TNF which are critically involved in pain
pathophysiology (Ji and Suter, 2007; Loram et al., 2010).
Previous studies have shown that NF-κB inhibitors decrease neuroinflammatory
pain-like symptoms. For example, reduction of neuroinflammatory pain was expected as
p50 (NF-κB) knock-out mice were refractory to induction of acute and chronic arthritis
(Campbell et al., 2000). Peripheral administration of NF-κB inhibitor decreases
neuropathic and neuroinflammatory pain-like symptoms (Tegeder et al., 2004). Also,
intrathecal administration of ammonium pyrrolidinedithiocarbamate and SN50, NF-κB
inhibitors, modulate neuroinflammatory pain-like symptoms in animal models (Ledeboer
et al., 2005). Taken together, these findings indicate that NF-κB and associated
mediators, including BDNF and proinflammatory cytokines such as TNF might be
potential therapeutic targets to modulate increased pain responses.
1.1.5. Cytokines
Cytokines are small proteins that constitutively express in precursor form on the
cell surface, and can be cleaved to allow release, from where upon they diffuse to act on
another cell (Austin and Moalem-Taylor, 2010). Microglial cells are considered as a main
source of cytokines in the CNS (Ji and Suter, 2007). Cytokines can be proinflammatory,
including TNF, interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-1 beta (IL-1β),
interferon-gamma (IFN-γ), interleukin-15 (IL-15), interleukin-17 (IL-17), and
interleukin-18 (IL-18); or anti-inflammatory, including transforming growth factor-beta
(TGF-β), interleukin-4 (IL-4), and interleukin-10 (IL-10). Among cytokines, TNF is
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indicated to be critically involved in neuroinflammatory pain development. Other
proinflammatory cytokines involved in producing painful behavior include IL-6, and IL1β.
1.1.6. The TNF and neuroinflammatory pain
The TNF, a major pro-inflammatory cytokine, has been known to be associated
with painful conditions (Austin and Moalem-Taylor, 2010). It is noteworthy to mention
that TNF induce its own production involving positive feedback mechanism, acting
synergistically to enhance the inflammatory response resulting in chronic inflammation
(Watkins et al., 1999). It has been indicated that increased TNF in the hippocampus
induces neuroinflammatory pain-like symptoms in animal models (Covey et al., 2000;
Ignatowski et al., 1999; Martuscello et al., 2012). Additionally, intracerebroventricular
(i.c.v.) injection of recombinant TNF induces neuroinflammatory pain-like symptoms
(Covey et al., 2002; Ignatowski et al., 1999; Oka et al., 1996).
The TNF mediates its effects involving constitutively expressed tumor necrosis
factor receptor 1 (TNFR1) receptors and inducible tumor necrosis factor receptor 2
(TNFR2) (MacEwan, 2002). TNFR1-mediated signaling is responsible for induction of
increased pain sensitivity while TNFR2 activation contributes to maintenance of pain-like
symptoms (Austin and Moalem-Taylor, 2010). As mentioned earlier, the binding of TNF
to its receptors, results in activation of NF-κB that causes increased production of
proinflammatory cytokines and pain hypersensitivity (Ledeboer et al., 2005; Wei et al.,
2007).
The TNF-mediated signaling can be modulated either by receptor antagonists, and
neutralizing antibodies that result in reversal of neuroinflammatory pain-like symptoms
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(Cuellar et al., 2004; Homma et al., 2002; Milligan et al., 2001). For example, etanercept
(circulating receptor fusion proteins), and infliximab (neutralising antibody) have been
shown to decrease neuroinflammatory pain-like symptoms (Sfikakis, 2010). However,
these drugs possess limited lipid solubility and cannot cross blood-brain barrier (BBB).
Taken together, these findings indicate that TNF is capable of supporting ongoing
inflammation and enhances pain transmission in animal models (Austin and MoalemTaylor, 2010). Moreover, TNF was shown to influence NE, a monoamine
neurotransmitter, release from noradrenergic neurons in the hippocampus (Covey et al.,
2000). Therefore, blocking TNF and increasing NE level in the hippocampus might have
therapeutic potential for neuroinflammatory pain (Austin and Moalem-Taylor, 2010; Ji
and Suter, 2007; Mika, 2008; Romero-Sandoval et al., 2008).
1.1.7. Monoamines neurotransmitters and neuroinflammatory pain
Monoamine neurotransmitters, including serotonin and NE play an important role
in pain behavior. Tricyclic antidepressants and selective serotonin norepinephrine
reuptake inhibitors used for neuroinflammatory pain have shown to work by increasing
serotonin and NE level. Previous studies have shown that NE level is reduced in the
hippocampus in pain hypersensitivity (Ignatowski et al., 1999). Moreover, NE and TNF
are signals of foremost importance that play very important role in painful behavior,
affecting each other level in the hippocampus. For example, the expression of NE
decreases as TNF increases in the hippocampus. Moreover, NE increases as TNF is
lowered in the hippocampus. Furthermore, increasing NE may alleviate pain sensitivity in
animal models. For example, it was shown that tricyclic antidepressants decrease pain by
reducing TNF expression and increasing NE level in the hippocampus (Reynolds et al.,
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2004). Taken together, these findings indicate that NE is critically involved in pain
hypersensitivity. The effects of microglial activation and associated pain mediators,
including TNF on NE level in the hippocampus are not known. Therefore, increasing NE
level in the hippocampus might have therapeutic utility for painful behavior involving
neuroimmune mechanisms.
1.1.8. The BDNF and neuroinflammatory pain
The BDNF plays a critical in neuroinflammatory pain development (Coull et al.,
2005; Groth and Aanonsen, 2002). It is produced by microglial cells in
neuroinflammatory pain involving NF-κB activation (Ji and Suter, 2007). Moreover,
BDNF is proposed to increase pain behavior due to increased expression of NKCC1 and
decreased KCC2 expression (Price et al., 2005). A pervious study has shown that
expression of BDNF is significantly increased in animal model of spinal nerve ligation
(Li et al., 2006) mediated by activated microglial cells (Coull et al., 2005; Cragg et al.,
2010). Microinjection of BDNF in CNS results in increased pain behavior in animal
models (Zhou et al., 2000). Furthermore, intraplantar injection of BDNF also results in
increased pain like symptoms in animal models (Shu and Mendell, 1999). Anti-BDNF
antibodies have been known to attenuate pain behavior in animal models (Quintao et al.,
2008). Moreover, administration of tyrosine receptor kinase B (TrkB) antibody also
reduced development of pain hypersensitivity (Yajima et al., 2002). Additionally,
sequestering BDNF using TrkB-Fc fusion protein also reduced development of pain
symptoms. Furthermore, knockdown of BDNF using siRNA prevents development of
pain behavior (Coull et al., 2005). Therefore, eliminating BDNF suppresses
neuroinflammatory pain in animal models (Zhao et al., 2006). Together, these findings
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indicate the possibility that BDNF might be required for neuroinflammatory pain
development in animal models and blocking microglial BDNF and targeting associated
proteins, including NKCC1, and KCC2 could be better strategy for the treatment of
neuroinflammatory pain.
1.1.9. The KCC2 and neuroinflammatory pain
The KKC2, a neuronal protein transporter, is responsible to maintain intracellular
Cl- concentration within neuron involving outward movement (Payne et al., 2003). Other
transporter involved in maintaining Cl- concentration within neuron is NKCC1. It was
found that reduction in the expression of KCC2 results painful behavior (Coull et al.,
2003). Previous study showed that down regulation of KCC2 plays a critical in
neuroinflammatory pain development (Cramer et al., 2008; Zhang et al., 2008).
Knockdown or blockade of KKC2 transporter induces neuroinflammatory pain-like
symptoms confirming that KKC2 is critically involved in neuroinflammatory pain
development (Price et al., 2005). Collectively, these findings indicate that reduced KCC2
expression is likely to be an important feature of painful condition and increasing KCC2
expression might be novel therapeutic strategy for neuroinflammatory pain.
1.1.10. The NKCC1 and neuroinflammatory pain
Electrical signaling through neurons is dependent on transporters, including
NKCC1 which like KCC2 is also responsible to maintain ion gradient (Payne et al.,
2003). NKCC1 is of particular interest with respect to neuronal chloride homeostasis and
is predominately expressed on neurons (Plotkin et al., 1997). The NKCC1 is involved for
the movement of Cl- into the cell (Haas, 1994; Plotkin et al., 1997). Research indicates
that NKCC1 plays a critical role in the pathophysiology of neuroinflammatory pain. For
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example, the expression and activity of NKCC1 increases in neuoinflammation resulting
in increased pain sensitivity (Galan and Cervero, 2005; Payne et al., 2003; Price et al.,
2005; Valencia-de Ita et al., 2006). This probably happens due to increased influx of Clwithin the neurons resulting in gamma amino butyric acid (GABA)-mediated disinhibition and increase pain sensitivity. Knockout mice have been shown to exhibit
reduced neuroinflammatory pain-like symptoms (Sung et al., 2000). Furthermore,
phosphorylation of NKCC1 (active NKCC1) results in increased pain behavior (Galan
and Cervero, 2005) . Thus activated NKCC1 has been found to induce
neuroinflammatory pain-like symptoms in animal models (Lee et al., 2014). Taken
together, these studies show that NKCC1 is critically involved in pain hypersensitivity
and blocking NKCC1 using nicotinic acetylcholine receptors (nAChRs) based neuroimmune modulators might be a novel target for neuroinflammatory pain treatment.
1.2. Brain nAChRs
Brain nicotinic nAChRs are ionotropic ligand gated cationic channels (Corringer
et al., 2000; Le Novere et al., 2002). The opening of nAChR channel is controlled by
acetylcholine (ACh) or nicotinic ligands. The nAChRs are permeable to both K+ and Na+
ions. Moreover, they are also permeable to Ca+2 ions which is affected by the
composition of subunits (Gotti et al., 2007). In CNS, nAChR are mainly presynaptic and
play a critical role in the release of neurotransmitters, including dopamine, NE, GABA,
and glutamate (Gotti et al., 2007). However, they are also present post-synaptically where
they mediate fast synaptic transmission (Dajas-Bailador and Wonnacott, 2004; Gotti and
Clementi, 2004; Jensen et al., 2005). Furthermore, they are also present on non-neuronal
cells, including microglial cells where they modulate neuroinflamatory response (Fucile,
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2004; Pocock and Kettenmann, 2007; Shytle et al., 2004). The interaction of nicotinic
ligands with nAChRs, results in arousal, fatigue, locomotion, sleep, anxiety, cognition,
and central processing of pain (Abbas and Rahman, 2016; Champtiaux and Changeux,
2002; Drago et al., 2003; Gotti and Clementi, 2004; Hogg and Bertrand, 2004; Hogg et
al., 2003; Picciotto et al., 2001; Picciotto et al., 2000).
The nAChRs are pentameric heterogeneous comprised of three β (β2-β4) and nine
α (α2-α10) subunits encoded by different genes. They consist of five homologous
subunits with four binding sites (heteropentameric; α7α8, α9α10) or two binding sites in
receptor molecule located between an α and a β subunit (α(α2– α6)-β(β2– β4)). Other
pentameric nAChRs are comprised of identical subunits with five similar ACh binding
sites in a receptor molecule (homopentameric; α7, α8, and α9) with a central pore
(Corringer et al., 2000; Le Novere et al., 2002).
The nAChRs are classified into two major classes, including α-bungarotoxinsensitive, and α-bungarotoxin-insensitive receptors. The α-bungarotoxin-sensitive
receptors which bind with α-bungarotoxin with high affinity consist of α7, α8, α9 and/or
α10 subunits. However, the α-bungarotoxin-insensitive receptors bind with nicotine and
other nicotinic agonists with high affinity, comprised of α2–6 and β2–4 subunits (Gotti et
al., 2006). In case of α-bungarotoxin-sensitive receptors, ACh binds either between two
identical subunits (α7, α8, α9) or different α subunits (α9–α10 or α7–α8). However, in
case of α-bungarotoxin-insensitive receptors, ACh binds between a α subunit and a β
subunit (Gotti et al., 2006). The use of asterisk (*) indicates the presence of nAChR
subunit that is unidentified.
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The nAChRs are widely distributed in the brain with α4β2 comprising about 90%.
The α4β2 receptors are distributed in cortex, hippocampus, striatum, amygdala, ventral
tegmental area, substantia nigra, thalamus, cerebellum, and hypothalalus. The α3β4 are
widely distributed in adrenal medulla, autonomic ganglia, dorsal medulla, medial
habenula, retina, and pineal gland (Gotti and Clementi, 2004). The α7 nAChRs are highly
expressed in the hippocampus, cortex, and sub cortical regions of brain limbic system and
at low levels in the basal ganglia and thalamic regions (Gotti et al., 2007; Gotti et al.,
2006). The α9 and α10 subunit containing receptors have been found in dorsal root of
gaglion, and pituitary gland in neurons and non-neuronal sites. Previous studies have
shown that α7 nAChRs are expressed on microglial cells and play a critical role in pain
control associated with neuro-inflammation (Abbas and Rahman, 2016; Pocock and
Kettenmann, 2007; Vincler et al., 2006). Therefore, targeting microglial α7 nAChRs and
associated signaling cascades might be better therapeutic strategy for pain control.
1.2.1. The α7 nAChRs
The α7 nAChRs are homomeric with five identical ACh binding sites (Drisdel
and Green, 2000) (Figure 2). They belong to neurotransmitter-gated ion channel super
family of receptors (Lukas et al., 1999). They are pentameric in nature (Drisdel and
Green, 2000), highly permeable to calcium and are undergo desensitization within
milliseconds on agonist binding (Couturier et al., 1990; Shen and Yakel, 2009). The α7
nAChRs are not only expressed in neurons but also on non-neuronal cells, including
microglial cells in CNS (Pocock and Kettenmann, 2007) and involve different signaling
pathways (Grybko et al., 2010; Wang et al., 2003).
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A previous study showed that anti-inflammatory reflex exists in the brain (de
Lucas-Cerrillo et al., 2011; Pavlov and Tracey, 2006; Shytle et al., 2004) mediated
through microglial α7 nAChRs to reduce neuroinflammation (Kawashima et al., 2012;
Mencel et al., 2013; Shytle et al., 2004). The activation of microglial α7 nAChRs results
in reduced production of proinflmammatory cytokines (Christie and Turnley, 2012; Pena
et al., 2010).
It is noteworthy to mention that cholinergic transmission in the brain is impaired
by various neurodegenerative diseases. The weakness of cholinergic system facilitate the
development of neuroinflammation specially by decreasing the ACh input to microglial
cells (Carnevale et al., 2007). Therefore, the α7 nAChR agonists are now considered as a
target for neuroinflammation and pain in animal models (Damaj et al., 2000; de Jonge
and Ulloa, 2007; Rowley et al., 2010; Wang et al., 2005). However, due to rapid
desensitization of α7 nAChRs because of agonist binding at othosteric site, microglial α7
nAChRs positive allosteric modulation could be potential approach for novel analgesic
development.
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Figure 2: Structure and organization of α7 nicotinic acetylcholine receptors (α7 nAChR).
(A) Pentameric arrangement of five identical α7 nAChR subunits arranged around central
pore. (B) Acetylcholine binds at each subunit and causes the increase in the intracellular
level of Na+1, K+1, Ca+2. Modified and adopted from Gotti and Clementi (2004) Prog
Neurobiology 74:363-396.
Unlike, neuronal α7 nAChR, microglial α7 nAChRs are metabotropic receptors
(Suzuki et al., 2006). The microglial α7 nAChRs differ from neuronal α7 nAChR in
terms of downstream signaling (Shytle et al., 2004; Suzuki et al., 2006). The activation of
microglial α7 nAChR causes the activation of phospholipase C and increased release of
Ca+2 from intracellular stores sensitive to inositol trisphosphate (Suzuki et al., 2006). This
then reduces NF-κB activation (Conejero-Goldberg et al., 2008; Egea et al., 2015; Loram
et al., 2010; Wang et al., 2004) involving inhibition of IκB degradation (Loram et al.,
2010; Tracey, 2009). The reduced activity of NF-κB decreases transcription of
proinflammatory cytokines and BDNF (Figure 3). For example, nicotine has been
indicated to inhibit NF-κB translocation into the nucleus in LPS-stimulated RAW 264.7
macrophages (Wang et al., 2004). Taken together, these findings indicate that microglial
α7 nAChR activation reduces proinflammatory cytokine and BDNF expression.
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Figure 3: Schematic illustrating the signaling cascade activated by α7 nicotinic
acetylcholine receptors (nAChRs) in microglia. Acetylcholine/choline activates α7
nAChRs resulting in increased intracellular Ca+2 which in turn reduces the degradation of
IκB thus inhibiting the translocation of p65 into nucleus. This results in the inhibition of
proinflammatory cytokine and brain-derived neurotrophic factor (BDNF) production.
Modified and adopted from Egea et al. (2015) Biochem Pharmacol 97:463-72.
The nAChRs have been known to be involved in the process of mediating pain.
The analgesic effects of nicotine were reported as early as 1932 (Bannon et al., 1998).
The microinjection of nicotine into different regions of the brainstem produced analgesic
effects (Umana et al., 2013). The analgesia produced by nicotine was further shown to be
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inhibited by the administration of the general nAChR antagonist, mecamylamine (Sahley
and Berntson, 1979). However, nicotine was not developed as anlagesic due to less
analgesic potential, low intrinsic activity, and side effects (Qian et al., 1993).
Apart from nicotine, the Ecuadorian frog skin-derived alkaloid epibatidine, which
acts as a nonselective agonist for nAChRs, was shown to have analgesic properties.
Epibatidine was able to reduce pain in the mouse straub tail model (Garraffo et al., 2009).
Upon further investigation, it was shown that epibatidine caused antinociception in
animal models of pain, it also produced several major adverse effects, including dosedependent decreases in locomotor activity, and body temperature. Moreover, since
epibatidine is a nonselective agonist, it activates multiple subtypes of the neuronal
nAChRs, as well as the neuromuscular receptor, which accounts for other side effects,
including neuromuscular paralysis, hypertension, and seizures at a dose closer to that
produces antinociceptive effects (Sullivan et al., 1994) limiting its use as a therapeutic
agent. Based upon these observations, the research focus has since shifted to develop
compounds that would selectively target specific nAChR subtypes such as microglial α7
nAChR with the purpose of maintaining the analgesic effect while reducing or
eliminating the adverse effects that are seen with nonselective agonists such as
epibatidine.
Compounds that involve α7 nAChRs agonism have also been studied for their
effects on pain behavior because of their distribution in pain pathways (Seguela et al.,
1993). Choline, a by-product of ACh enzymatic degradation by acetyl cholinesterase and
a selective agonist for the α7 receptors, has analgesic effects in rodent models of pain
(Loram et al., 2010; Wang et al., 2005). Systemic administration of an α7 nAChR
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agonist, TC-7020, reverses neuropathic pain in animal models (Loram et al., 2012). A
previous study showed that i.c.v. administration of citicoline, precursor for choline, was
effective in inflammatory pain models (Bagdas et al., 2011). However, α7 nAChRs
undergo rapid desensitization on agonist binding in neuroinflammatory pain where
continuous stimulation of microglial α7 nAChRs is needed to inhibit neuroinflammation.
The mechanism through which α7 nAChRs undergo desensitization is not known. One
alternative approach to prevent desensitization of α7 nAChR is by the use of α7 nAChR
positive allosteric modulators (PAMs).
1.2.2. The α7 nAChR PAMs
The term allosteric modulation indicates that protein can exist in various multiple
conformational states and binding of allosteric compound changes the energy barrier
between these states. For example, ACh binds at interface between subunit protomers
(othosteric site) while a molecule that binds elsewhere on the protein works as allosteric
modulator thus stabilizing the protein in preferential state (Changeux and Edelstein,
2005). For example, in case of α7 nAChR, the allosteric compound stabilizes the protein
in active open state. PAMs increase the gain of the physiological response without having
an inappropriate tonic response. In other words, PAMs enhance the activity induced by
agonists and exhibit no intrinsic activity (Abdrakhmanova et al., 2010; Arias, 2010;
Bertrand and Gopalakrishnan, 2007).
The α7 nAChR function can be modulated by endogenous peptide, including
SLURP-1 (secreted mammalian Ly-6/uroquinase plasminogen activated receptor related
protein 1) which works as endogenous PAM of α7 nAChRs (Atzori et al., 2016). The
PAMs have been classified as either type I, such as NS1738 (Arias, 2010; Haydar and
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Dunlop, 2010; Mazurov et al., 2011; Williams et al., 2011), or type II, such as 3a,4,5,9btetrahydro-4-(1-naphthalenyl)-3H-cyclopentan[c]quinoline-8-sulfonamide (TQS) (Arias,
2010; Gill et al., 2011; Gronlien et al., 2007) on the basis of their effects on
desensitization (Bertrand and Gopalakrishnan, 2007; Timmermann et al., 2007). The
PAMs with little or no effect on desensitization are classified as type I PAMs and those
that cause a dramatic reduction in agonist-induced desensitization of α7 nAChR are
known as type II PAMs (Chatzidaki et al., 2015). Therefore, type II PAMs modifies the
equilibrium between active and desensitized state that result in significantly prolonged
responses (Gronlien et al., 2007; Hurst et al., 2013; Hurst et al., 2005; Roncarati et al.,
2008b). Furthermore, type II PAMs promote the activation of receptors that are
previously desensitized (Hurst et al., 2005).
The TQS is a selective α7 nAChR type II PAM (Arias, 2010; Gronlien et al.,
2007). Being lipophilic compound, TQS is expected to cross BBB. The TQS alone has no
intrinsic activity at α7 nAChR and is a potent α7 nAChR PAM when co-applied with
ACh (Gill et al., 2012; Gill et al., 2011; Gronlien et al., 2007). Furthermore, TQS is
known to facilitate the recovery of complete agonist-induced desensitization of α7
nAChRs (Couturier et al., 1990; Gill et al., 2012; Gill et al., 2011) (Figure 4). The
effectiveness of TQS in neuroinflammatory pain has not been investigated yet.
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Figure 4: Schematic representation α7 nicotinic acetylcholine receptor (nAChR)
desensitization and role of TQS. Binding of α7 nAChR ligand i.e acetylcholine/choline
causes the desensitization of α7 nAChR. TQS binds at allosteric site of α7 nAChR and
prevents the desensitization induced by acetylcholine/choline. Modified and adopted
from Hurst et al. (2013) Pharmacol Ther 137:22-54.
Due to receptor desensitization by α7 agonists, research has focused on α7
nAChR PAMs (Papke et al., 2009). Studies have reported that α7 nACh PAMs facilitate
endogenous neurotransmission, and enhance the potency and efficacy of an agonist
without directly stimulating the orthosteric site. Thus, these compounds augment and
synergize orthosteric site-mediated signaling of endogenous neurotransmitters, including
choline, and ACh. In principle, PAMs do not exhibit intrinsic activity at the receptor;
however they can increase endogenous cholinergic neurotransmission. These PAMs are
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shown to increase maximal efficacy and the potency of endogenous (choline or ACh) or
exogenous agonists for the α7 nAChRs. A variety of α7 nAChR PAMs have been
evaluated in preclinical models for pain. For instance, PNU-120596, an α7 nAChR PAM,
resulted in a significant reduction in mechanical hyperalgesia in rats (Munro et al., 2012).
Additionally, PNU-120596 is able to decrease formalin-induced pain by alone, and in
combination with the α7 nAChR agonists, including choline, nicotine, and PHA-543613
(Freitas et al., 2013). Another α7 nAChR PAM, NS-1738, has also been tested for its
effects on pain. Both NS-1738 and PNU-120596 were able to reduce heat-induced
hyperalgesia (Freitas et al., 2013). However, the effects of α7 nAChR PAMs on
microglial activation and associated signaling in the hippocampus are not known.
Therefore, we hypothesized that α7 nAChR positive allosteric modulation in the
hippocampus will be novel therapeutic strategy for neuroinflammatory pain treatment.
1.3. Rationale and objectives
Microglial cells play a critical role in neuroinflammatory pain development and
maintenance in the CNS. As described earlier, the microglial cells become active
involving NF-κB activation in neuroinflammatory pain. The NF-κB-mediated gene
expression causes the release of pain mediators, including TNF, and BDNF. The TNF in
turn affects the release of NE while BDNF is involved in the regulation of NKCC1 and
KCC2 in pain pathology. Previous studies have shown that cholinergic nicotinic pathway
exists in the hippocampus which modulates microglial activation involving α7 nAChRs
(Pavlov and Tracey, 2006; Shytle et al., 2004). As a part of the limbic system, the
hippocampus is known to play a critical role in pain perception and processing. The
effects of microglial α7 nAChR on microglial activation and associated pain mediators in
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the hippocampus are not known in neuroinflammatory pain. Since α7 nAChRs undergo
rapid desensitization, we hypothesized that targeting α7 nAChRs through positive
allosteric modulation (i.e. at allosteric binding site) and associated mechanisms will be a
better strategy to treat neuroinflammatory pain.
The overall goal of this dissertation is to determine the role of α7 nAChR PAM in
neuroinflammatory pain. The primary objectives of research presented in this dissertation
include
i.

To determine the effects of α7 nAChR ligand on neuroinflammatory pain and
microglial activation in neuroinflammatory pain.

ii.

To elucidate the effects of α7 nAChR ligand on NF-κB activation in the
hippocampus in neuroinflammatory pain.

iii.

To examine the effects of α7 nAChR ligand on TNF expression and NE level in
the hippocampus in neuroinflammatory pain.

iv.

To determine the effects of α7 nAChR ligand on BDNF expression in the
hippocampus in neuroinflammatory pain

v.

To examine the effects of α7 nAChR ligand on NKCC1 and KCC2 expression in
the hippocampus in neuroinflammatory pain.
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Chapter 2: Effects of α7 nAChR PAM on LPS-induced neuroinflammatory pain and
microglial activation in the hippocampus in mice
2.1. Introduction
As described in chapter 1, the α7 nAChRs have been implicated in the modulation of
pain in animal models and are widely distributed on non-neuronal cells such as microglial
cells in CNS, including hippocampus (Dineley et al., 2015; Gaimarri et al., 2007; Vincler,
2005). Consistent with previous studies, cholinergic nicotinic pathway exists in the
hippocampus involving microglial α7 nAChRs (Shytle et al., 2004). The cholinergic
nicotinic pathway in the hippocampus has been found to regulate neuroinflammation.
During neuroinflammation, microglia cells rapidly change from a resting state to an
active state and produce variety of mediators, including Iba-1, the microglial activation
marker (Yoon et al., 2012). Therefore, increased expression of Iba-1 corresponds to the
severity of microglial activation in neuroinflammation. Previous studies showed that
microglial activation in the CNS plays a critical role in the onset and maintenance of
neuroinflammatory pain (Austin and Moalem-Taylor, 2010; Yoon et al., 2012).
The LPS, an exogenous ligand for TLR4, is widely implicated for microglial
activation in the CNS (Silverman et al., 2014). Recent studies indicate that LPS increases
nociceptive sensitivity to pain stimuli resulting in allodynia and thermal hyperalgesia
likely due to increased microglial activation in the CNS (Yoon et al., 2012). Moreover,
the α7 nAChR agonists have been found to reduce neuroinflammatory pain in preclinical
studies due to their ability to decrease CNS microglial activation (Loram et al., 2010;
Pocock and Kettenmann, 2007). Therefore, α7 nAChR PAM, including TQS might be
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better therapeutic candidate for neuroinflammatory pain likely due to its ability in inhibit
α7 nAChR desensitization.
Methyllcaconitine (MLA) is a norditerpenoid alkaloid and potent competitive α7
nAChR antagonist (Davies et al., 1999; Holladay et al., 1997; Williams et al., 1994). The
MLA possesses high affinity for α7 nAChR (Sharples and Wonnacott, 2001). The MLA
has been known to cross BBB after peripheral administration (Turek et al., 1995). It has
been indicated to block α7 nAChR-mediated effects in animal models (Callahan et al.,
2013; Freitas et al., 2013). Therefore, MLA is used to examine the CNS effects of the α7
nAChR during in vivo studies (Turek et al., 1995).
Given this, the evidence supports the involvement of microglial cells in
neuroinflammatory pain involving α7 nAChR in the CNS, The TQS might exert similar
effects on hippocampal microglial cells, thus decreasing microglial activation and
neuroinflammatory pain. Therefore, we hypothesized that TQS will reduce microglial
activation associated pain by reducing LPS-induced microglial activation in the
hippocampus. In the present study, we examined the antihyperalgesic and antiallodynic
effects of TQS following systemic administration of LPS in mice model. Moreover, we
examined the effects of MLA on TQS-induced antiallodynic and antihyperalgesic effects.
Additionally, we have determined the effects of TQS on microglial Iba-1 expression in
the hippocampus in mice.
2.2. Methods
Animals
All experiments were conducted on male C57BL/6J mice purchased from Jackson
Laboratory (Bar Harbor, ME, USA). Animals were housed in groups of four in standard
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shoebox cages (29×18×12 cm), under standard laboratory conditions (22 ± 2 °C, relative
humidity 50–60%) and maintained on a 12-h light/dark cycle (lights on at 0600 h) with
unlimited access to food and water. Mice were 10–12 weeks of age at the beginning of
the experiment. The behavioral experiments were carried out between 0900 and 1600 h in
a blind manner with respect to drug treatment. All procedures were in compliance with
the National Institutes of Health guidelines for the Care and Use of Laboratory Animals
and were approved by the Institutional Animal Care and Use Committee at South Dakota
State University. Good Laboratory Practice and ARRIVE guidelines were obeyed. All
efforts were attempted to ensure least animal suffering.
Drug treatment
Lyophilized LPS (Escherichia coli, serotype 055:B5) and MLA were purchased from
Sigma-Aldrich (St. Louis, MO, USA) and were dissolved in normal saline (0.9% NaCl).
TQS was purchased from Tocris Bioscience (Ellisville, MO, USA) and was reconstituted
in normal saline containing 1% dimethyl sulphoxide (DMSO) and 0.5% tween 80. Mice
received TQS (1 or 4 mg/kg) 0.5 h before LPS administration. The MLA was injected 10
min before TQS injection. All drugs were administered intraperitoneally (i.p.) in a
volume of 10 ml/kg of body weight.
Induction of tactile allodynia and thermal hyperalgesia
Tactile allodynia and thermal hyperalgesia were induced by LPS (1 mg/kg, i.p.)
administered six hours (h) before measurement of tactile allodynia and thermal
hyperalgesia as described previously with minor modification (Yoon et al., 2012).
Control animals were given an equal volume of vehicle.
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Tactile allodynia
A standardized testing method was used to measure tactile allodynia as described
previously (Chaplan et al., 1994), six h following LPS administration. Briefly, mice were
acclimatized to the wire mesh boxes (Stoelting, Inc., Wood Dale, IL, USA) for 4
successive days prior to testing for tactile allodynia. On the day of testing, mice were
permitted to habituate for 30 + 5 min. A logarithmic series of calibrated von Frey
filaments (Stoelting, Inc., Wood Dale, IL, USA) were to determine 50% paw withdrawal
threshold using up-down method of Dixon with minor modification (Dixon, 1980). A
series of filaments beginning with one that had 0.16 g buckling weight were applied
vertically to right/left hind paw at its plantar surface. Lifting of the right/left hind paw
was noted as positive score and the next light force filament was then applied for second
measurement. If paw withdrawal did not happen within 5 seconds (s) of application, the
next higher filament was applied. This process was continued until four readings were
taken after initial positive response or until five successive negative scores (0.6, 1, 1.4, 2;
2.0 g score was assigned) or four consecutive positive measurements (0.16, 0.07, 0.04,
0.02, 0.008; 0.008 g score was assigned). Von Frey filaments were applied at several s of
intervals thus leading to resolution of any behavioral response to earlier stimulus.
Ambulation was noted as ambiguous response, and if it happened, stimulus was repeated.
The resulting chain of positive and negative scores was used to calculate 50% paw
withdrawal threshold. 50% g paw withdrawal threshold = (10(Xf + Kδ)/10000, Where K=
tubular value for pattern of positive and negative responses, Xf = Log value of final von
Frey filament force use, and δ=Log value of mean difference between stimuli.
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Thermal hyperalgesia
Thermal hyperalgesia was determined six h following LPS administration by
measuring changes in hind paw withdrawal latency using a plantar analgesia apparatus
(IITC Life Science Inc., Woodland Hills, CA) as described previously (Yoon et al.,
2012). Briefly, paw withdrawal (latency time) was determined using an intense heat
source to stimulate thermoreceptor in the sole of the foot. Each mouse was subjected to
latency on hot plate maintained at 54.0 + 0.1oC in a plexiglas chamber. Animals jumping,
licking or flicking was noted as positive measurement. Latency for each mouse was noted
as a mean of three readings. Thirty s was chosen as a cut-off time to avoid tissue damage.
Western blot analysis
Mice were sacrificed six h later LPS administration, their hippocampi were dissected
out, frozen in dry ice, and stored at −80°C until further analysis. Western blot analysis
was carried out as described previously with minor modifications (Yoon et al., 2012).
Briefly, brain tissue samples were homogenized in RIPA buffer having Dulbecco’s
Phosphate-buffered saline (Atlanta Biologicals, Lawrenceville, GA, USA), 1% Igepal
CA-630 (Sigma-Aldrich, St. Louis, MO, USA), 0.1% sodium dodecyl sulfate (Fisher
Scientific, Fair Lawn, New Jersey, USA), and protease inhibitor mix (complete, Mini,
Roche, Indianapolis, IN, USA). Each sample was then centrifuged (17,000×g, 20 min at
4°C) and supernatant was collected. Total protein concentration in the hippocampal
samples was measured by bicinchoninic acid assay (Pierce, Rockford, IL, USA). Equal
amounts of protein (50 μg) were loaded onto 12% gels for sodium dodecyl sulfate
polyacrylamide gel electrophoresis using electrophoresis unit (Amersham Biosciences,
San Francisco, CA, USA). Separated proteins were then transferred onto nitrocellulose
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membranes (Santa Cruz Biotechnology, Dallas, Texas, USA) at 40 V overnight using
Mini Tank Transfer Unit (Amersham Biosciences, San Francisco, CA, USA).
Membranes were then blocked on a gyro-rocker having 5% nonfat dry milk in trisbuffered saline/0.1% tween-20 for 50 min, and subsequently incubated overnight at 4°C
with primary antibodies for Iba-1 (goat anti-rabbit-Iba-1; 1:1000, Wako, Osaka, Japan),
or β-tubulin (E7-S, 1:5,000, mouse monoclonal, University of Iowa, USA). After
incubation with primary antibody, membranes were incubated with proper horseradish
peroxide-conjugated secondary antibodies (Santa Cruz Biotechnology, Dallas, Texas,
USA). Bound antibodies were then detected with enhanced chemiluminescence prime
reagent (Amersham, Buckinghamshire, UK), and protein quantification was determined
using densitometric analysis. Western blot image that was close to average was chosen as
representative image.
Statistical analyses
For hyperalgesia, data were analyzed by one-way analysis of variance (ANOVA)
followed by Tukey’s post hoc test for multiple comparisons or Student’s t-test for MLA
data. For tactile allodynia, Kruskal-Wallis test followed by Dunn’s post hoc test for
multiple comparisons or Mann-Whitney test for MLA data was used. Data from Western
blot studies were expressed as Iba-1/β-tubulin expression (% control) and were analyzed
by one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons using
GraphPad Prism 5.0 (GraphPad Inc., San Diego, CA, USA). The difference between
treatments was considered significant at P < 0.05. All results are expressed as mean ±
standard error of mean (S.E.M.).

34
2.3. Results
Effects of TQS on 50% paw withdrawal threshold during von Frey filament test in LPSinduced neuroinflammatory pain
The effects of TQS on 50% paw withdrawal (tactile allodynia) are shown in the
Figure 5. The results from Kruskal-Wallis test showed that TQS pretreatment
significantly affected 50% paw withdrawal threshold in von Frey filament test (P <
0.0001). Dunn’s post hoc test for multiple comparison showed that LPS (1 mg/kg)
significantly (P < 0.001) decreased 50% paw withdrawal threshold as compared to
control indicating the presence of tactile allodynia. Moreover, TQS (4 mg/kg)
significantly (P < 0.01) increased 50% paw withdrawal threshold compared to LPS
treatment group indicating significant antiallodynic response.
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Figure 5: Lipopolysaccharide (LPS) significantly decreased 50% paw withdrawal
threshold (tactile allodynia) compared to control. Moreover, TQS significantly increased
50% paw withdrawal threshold compared to LPS treated group. Mice received TQS (1 or
4 mg/kg, i.p.) 0.5 h before the administration of LPS. Control animals received equal
volume of vehicle. Paw withdrawal threshold was measured using von Frey filaments six
h after LPS administration. Data are expressed as mean + S.E.M. (n = 7-8/group). *P <
0.01; **P < 0.001.
Effects of TQS on 50% paw withdrawal threshold in von Frey filament test
The effects of TQS on 50% paw withdrawal (tactile allodynia) are shown in the
Figure 6. The results from Kruskal-Wallis test showed that TQS did not significantly
affect 50% paw withdrawal threshold in von Frey filament test.
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Figure 6: TQS (1 or 4 mg/kg, i.p.) did not significantly affect 50% paw withdrawal
(tactile allodynia) in von Frey filament test. Mice received TQS (1 or 4 mg/kg, i.p.) 0.5 h
before the administration of saline (Sal). Control animals received equal volume of
vehicle. Paw withdrawal threshold was measured using von Frey filaments six h after Sal
administration. Data are expressed as mean + S.E.M. (n = 4-7/group).
Effects of TQS on latency time during hot plate test in LPS-induced neuroinflammatory
pain
The effects of TQS on latency time (thermal hyperalgesia) in hot plate test (54.0 +
1oC) are shown in Figure 7. The results from One way ANOVA showed that TQS
pretreatment significantly changed latency time in hot plate test (F3,20 = 8.359; P <
0.001). Multiple comparisons of means indicated that LPS (1 mg/kg) significantly (P <
0.001) reduced latency time on hot plate as compared to control showing significant
reduction in response to heat stimulus. Moreover, TQS (4 mg/kg) significantly (P < 0.01)
increased latency time on hot plate as compared to LPS treatment group indicating
administration of TQS prevented the development of thermal hyperalgesia.
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Figure 7: Lipopolysaccharide (LPS) significantly decreased latency time (thermal
hyperalgesia) on the hot plate. Moreover, TQS significantly increased latency time on hot
plate compared to LPS treated group. Mice received TQS (1 or 4 mg/kg, i.p.) 0.5 h before
the administration of LPS. Control animals were given equal volume of vehicle. Latency
on hot plate was determined six h after LPS administration. Data are expressed as mean
+ S.E.M. (n = 6/group). *P < 0.01; **P < 0.001.
Effects of TQS on latency time in hot plate test
The effects of TQS on latency time (thermal hyperalgesia) in hot plate test (54.0 +
1oC) are shown in Figure 8. The results from one way ANOVA showed that TQS did not
significantly change latency time in hot plate test (F2,11 = 0.8660; P > 0.05).
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Figure 8: TQS (1 or 4 mg/kg, i.p.) did not significantly change latency time (thermal
hyperalgesia) on the hot plate. Mice received TQS (1 or 4 mg/kg, i.p.) 0.5 h before the
administration of saline (Sal). Control animals were given equal volume of vehicle.
Latency on hot plate was determined six h after Sal administration. Data are expressed as
mean + S.E.M. (n = 4-5/group).
Effects of MLA on TQS-induced antiallodynic response in von Frey filament test
The effects of MLA on TQS-induced antiallodynic response are shown in the
Figure 9. The results from Mann-Whitney test showed that MLA (3 mg/kg) pretreatment
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significantly (P < 0.01) reduced 50% paw withdrawal threshold compared to TQS
treatment group, validating that antiallodynic effects of TQS are mediated by α7 nAChR.

Figure 9: Lipolpolysaccharide (LPS) significantly decreased 50% paw withdrawal
threshold (tactile allodynia) compared to control. Moreover, TQS significantly increased
50% paw withdrawal threshold compared to LPS treatment group. Methyllycaconitine
(MLA) significantly reduced 50% paw withdrawal threshold compared to TQS treatment
group. Mice were given TQS (4 mg/kg, i.p.) 0.5 h before LPS administration. Animals
received MLA (3 mg/kg, i.p.) ten min before TQS injection. Control animals received
equal volume of vehicle. Paw withdrawal threshold was measured using von Frey
filaments six h after LPS administration. Data are expressed as mean + S.E.M. (n = 68/group). *P < 0.01; **P < 0.001.
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Effects of MLA on TQS-induced antihyperalgesic response in hot plate test
The effects of MLA on TQS-induced antihyperalgesic response are shown in the
Figure 10. Results from Student’s t-test showed that MLA (3 mg/kg) pretreatment
significantly (P < 0.001) decreased latency time on hot plate as compared to TQS
treatment group, indicating that MLA significantly reduced antihyperalgesic effects of
TQS mediated through α7 nAChR. This validated the involvement of α7 nAChR in the
mediation of antihyperalgesic effects of TQS.
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Figure 10: Lipolpolysaccharide (LPS) significantly decreased 50% latency time (thermal
hyperalgesia) on hot plate compared to control. Moreover, TQS significantly increased
latency time on hot plate compared to LPS treatment group. Methyllycaconitine
(MLA) significantly reduced latency time on the compared to TQS treatment group. Mice
received TQS (4 mg/kg, i.p.) 0.5 h before LPS administration. The MLA (3 mg/kg, i.p.)
was administered 10 min before TQS injection. Control animals received equal volume
of vehicle. Latency on hot plate was measured six h after LPS administration. Data are
expressed as mean + S.E.M. (n = 6/group). *P < 0.01; **P < 0.001.
Effects of TQS on LPS-induced increased Iba-1 expression in hippocampus
The effects of TQS on Iba-1 exprssion in the hippocampus are shown in the
Figure 11. The results from one way ANOVA showed that TQS pretreatment
significantly affected Iba-1 expression in the hippocampus (F3,23 = 12.90; P < 0.0001).
Multiple comparisons of means showed that LPS (1 mg/kg) significantly (P < 0.01)
increased the expression of Iba-1 in the hippocampus as compared to control indicating
that administration of LPS activated microglial cells in the hippocampus. Additionally,
TQS (1 or 4 mg/kg) significantly (P < 0.01 or P < 0.001) reduced Iba-1 expression in the
hippocampus as compared to LPS treatment group. This showed that antiallodynic and
antihyperalgesic effects of TQS are mediated through the inhibition of microglial
activation in the hippocampus.
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Figure 11: Lipolpolysaccharide (LPS) significantly increased the expression of ionized
calcium-binding adapter molecule 1 (Iba-1) compared to control in the hippocampus.
Furthermore, TQS (1 or 4 mg/kg, i.p.) significantly reduced Iba-1 expression in the
hippocampus compared to LPS treated group. Animals received TQS (1 or 4 mg/kg, i.p.)
0.5 h before LPS administration. Control animals received equal volume of vehicle.
Hippocampi were collected 6 h after LPS administration. Representative Western blots
for Iba-1 expression from hippocampus (top panel). Data are expressed as mean + S.E.M.
(n = 6-7/group). *P < 0.01; **P < 0.001.
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2.4. Discussion
The data from current study demonstrated the effectiveness of TQS in LPS-induced
neuroinflammatory pain. Our findings indicate that pretreatment of TQS, an α7 nAChR
PAM, dose-dependently produced antiallodynic and antihyperalgesic effects in LPSinduced neuroinflammatory pain model. These analgesic effects were reversed by MLA,
an antagonist at α7 nAChR, indicating the involvement of α7 nAChR. In addition,
pretreatment of TQS significantly reduced the LPS-induced increase in hippocampal Iba1, a microglial activation marker, expression suggestive the inhibition of hippocampal
microglial activation resulted in reversal of tactile allodynia and thermal hyperalgesia in
our mice model.
Previous studies have indicated that α7 nAChR agonists reduce pain hypersensitivity
in animal models. For example, α7 nAChR selective agonists effectively decrease
neuropathic and neuroinflammatory pain-like symptoms in animal models (Feuerbach et
al., 2009; Loram et al., 2010; Loram et al., 2012). Choline, an α7 nAChR agonist and
metabolite of ACh, was found to reduce in postoperative pain in animal models (Rowley
et al., 2010; Rowley et al., 2008). Additionally, i.c.v. injection of citicoline, precursor for
choline, was effective in inflammatory pain models (Bagdas et al., 2011). However, as
reported earlier, α7 nAChRs become rapidly desensitized in the presence of agonist
(Papke et al., 2009). One alternative approach is to selectively increase the activity of α7
nAChRs agonists at α7 nAChRs is through PAMs (Freitas et al., 2013; Munro et al.,
2012; Williams et al., 2011).
Previous studies have shown that PAMs facilitate endogenous neurotransmission and
increase the efficacy and potency of an agonist without directly stimulating the agonist
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binding site (Williams et al., 2011). In principle, the α7 nAChRs PAMs do not show
intrinsic activity at the receptor, however, they enhance endogenous cholinergic
neurotransmission (Freitas et al., 2013). These α7 nAChRs PAMs have been classified as
either type I, such as NS1738, or type II, such as TQS, based on difference in their effects
on receptor desensitization (Collins et al., 2011). Type I PAMs have negligible effect on
desensitization kinetics, whereas type II PAMs can efficaciously prevent desensitization
and reactivate already desensitized α7 nAChRs (Gronlien et al., 2007). Administration of
α7 nAChRs type II PAM is associated with decreased pain sensitivity in animal models
(Alsharari et al., 2013; Freitas et al., 2013; Munro et al., 2012; Pacini et al., 2010).
The data presented in this study indicated for the first time that pretreatment of TQS
reduced both thermal hyperalgesia and tactile allodynia in our mouse model. Taken
together, these data support our findings regarding the effectiveness of TQS in inhibiting
tactile allodynia and thermal hyperalgesia induced by LPS. Our results also demonstrate
that antiallodynic and antihyperalgesic effects of TQS are linked with α7 nAChRs
activation since prior treatment with MLA completely reversed the effects produced by
TQS. To the best of our knowledge, we report for the first time that in neuroinflammatory
pain model, TQS blocked tactile allodynia and thermal hyperalgesia in an a α7 nAChR
specific manner. Therefore, these results strongly support the involvement of α7 nAChRs
positive allosteric modulation in pain transmission in the CNS.
Although microglial cells are considered as scavenger cells in the CNS, emerging
evidence indicates that microglial cells actively communicate with neurons and
substantially contribute to the pathophysiology of various types of neurodegenerative
disorders such as neuroinflammatory pain (Carnevale et al., 2007). Activation of
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microglial cells is now known as being fundamentally important in the induction and
maintenance of pathological pain conditions in animal models involving α7 nAChRs in
the CNS (Loram et al., 2010; Medhurst et al., 2008). Microglial cells experience rapid
activation in the CNS due to pathological events, and provide a strong force for
pathological pain conditions such as neuroinflammatory pain (Yoon et al., 2012; Zhuo et
al., 2011). For example, peripheral nerve injury mediates increased expression of
microglial activation marker, including Iba-1 (Garrison et al., 1991). Additionally,
studies have indicated that microglial activation is adequate to induce pain
hypersensitivity in animal models (Tsuda et al., 2003). Therefore, reducing microglial
activation may have potential therapeutic utility for painful sensation and/or neurological
disorders.
The clinical potential of targeting activated microglial cells is now becoming highly
recognized but is still in its infancy stage due to identification of optimal drug targets for
controlling neuroinflammatory pain associated with microglial activation (Wen et al.,
2011; Zhuo et al., 2011). For example, microglial inhibitors such propentofylline reduce
pain hypersensitivity (Sweitzer et al., 2001). Conversely, fractalkine, the microglial
activator, results in development of behavioral signs of neuroinflammatory pain,
including tactile allodynia, and thermal hyperalgesia (Milligan et al., 2004).
Previous studies showed that systemic injection of LPS resulted in microglial
activation due to increased morphological changes associated with increased Iba-1
expression in the hippocampus compared to most of other brain regions (Silverman et al.,
2014). Moreover, microglial cells were found to be densely populated in the
hippocampus as compared to other brain regions, including brainstem (Lawson et al.,
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1990). Additionally, α7 nAChRs are expressed at higher density in the hippocampus than
in most of the CNS regions (Gaimarri et al., 2007; Gotti et al., 2006; Picciotto et al.,
2000) indicating TQS might exert α7 nAChR-mediated effects more in hippocampus than
in other brain regions. Furthermore, cholinergic nicotinic pathway has been proposed to
exist in the hippocampus that plays very important role in the inhibition of microglial
activation involving α7 nAChRs (Shytle et al., 2004). Thus, decreasing microglial
activation in the hippocampus through α7 nAChRs may have therapeutic potential for
neuroinflammatory pain.
In line with these reports, we noted that LPS increases the Iba-1 expression in the
hippocampus in our neuroinflammatory pain model. Clearly, these findings indicate that
there might be a correlation between hippocampal microglial activation and
neuroinflammatory pain following LPS administration. We have also found that TQS
reduces the activation of microglial cells in the hippocampus as indicated by reduced Iba1 expression during antiallodynic and antihyperalgesic response. This observation also
supports the role of microglial cells in the active modulation of neuroinflammatory painlike symptoms. Taken together, we propose that antiallodynic and antihyperalgesic
effects of TQS are likely due to reduced hippocampal microglial activation involving α7
nAChRs.
The underlying mechanisms involved in the antiallodynic and antihyperalgesic effects
of TQS in neuroinflammatory pain models are currently not known. Previous studies
have demonstrated that NF-κB becomes activated during microglial activation (Loram et
al., 2010; Uesugi et al., 2006) and NF-κB stimulated gene expression contributes to the
development of increased excitability of nociceptive neurons. Hence, NF-κB inhibition in

47
the hippocampus is possibly important tool for the significant antiallodynic and
antihyperalgesic effects of TQS. Therefore, subsequent studies are required to examine
how TQS affects hippocampal microglial cells beyond the expression of activation
marker, including the quantification of NF-κB expression. It is noteworthy to mention
that TQS could increase endogenous cholinergic transmission through α7 nAChRs in the
hippocampus, reducing pain-related behavior involving inhibition of NF-κB activation.
The central effects of TQS may widen its potential for clinical usefulness for
neuroinflammatory pain as neuroinflammatory pain-like symptoms are possibly mediated
by activated microglial cells. Therefore, the results from this study indicate that α7
nAChR-dependent mechanisms are critically involved in the modulation of
neuroinflammatory pain-like symptoms in this mouse model.
In conclusion, our data indicate that antiallodynic and antihyperalgesic effects
produced by TQS might be due to positive allosteric modulation of α7 nAChRs on
microglial cells likely in the hippocampus. The evidence further supports the concept that
α7 nAChRs PAM might represent novel and attractive therapeutic target for treating
referred tactile allodynia and thermal hyperalgesia associated with microglial activation
in neuroinflammatory pain.
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Chapter 3: Effects of α7 nAChR PAM on NF-κB activation in the hippocampus
3.1. Introduction
We have demonstrated that TQS reduces neuroinflammatory pain by decreasing
microglial activation in the hippocampus (see chapter 2). It was shown that NF-κB
increases in the hippocampus in painful conditions (Chou et al., 2011). Moreover,
previous studies showed that microglial α7 nAChRs activation causes increased NF-κB
inactivation in neuroinflammatory pain involving enhanced expression of IκB mRNA
(Egea et al., 2015; Loram et al., 2010). However, as reported earlier, these receptors
undergo rapid desensitization upon agonist binding at orthosteric site (Papke et al., 2009),
and adopt non-conducting conformation (Williams et al., 2011). The α7 nAChR type II
PAMs which prevent α7 nAChR desensitization are known to reduce pain
hypersensitivity in animal models at spinal level (Bagdas et al., 2016; Freitas et al., 2013;
Munro et al., 2012). However, the antialloydynic and antihyperalgesic effects of α7
nAChR type II PAMs in the hippocampus are not examined yet.
The evidence suggests that hippocampus is critically involved in pain production
and maintenance and involves dentate gyrus (DG) (Soleimannejad et al., 2007), and CA1
(Khanna and Sinclair, 1989; Martuscello et al., 2012) regions. Compared to other brain
regions, DG and CA1 regions of hippocampus are highly populated with microglial
cells (Lawson et al., 1990), indicating a potential role of hippocampal microglia in
neuroinflammatory pain. Furthermore, evidence suggests that activated NF-κB within
microglial cells are important regulators in neuroinflammatory pain development (Loram
et al., 2010; Watkins et al., 2001; Zhuo et al., 2011). Telmisartan (TEL), was found to
exhibit activity in neuropathic pain (Jaggi and Singh, 2011) in animal models.
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Furthermore, TEL was reported to reduce LPS-induced NF-κB activation within
macrophages (Balaji and Ramanathan, 2014; Saavedra, 2012). Therefore, NF-κB has
emerged as potential target of great importance due to its dysregulation in
neuroinflammatory pain conditions (Loram et al., 2010). Therefore, targeting activated
NF-κB within hippocampal microglia through α7 nAChRs positive allosteric modulation
might have therapeutic utility for neuroinflammatory pain.
Emerging evidence suggests that microglial cells play a very important role in the
maintenance of neuroinflammatory pain state involving activated NF-κB and enhanced
CD11b expression, a microglial activation marker in the CNS (Loram et al., 2010; Tsuda
et al., 2005; Watkins et al., 2001). Previous studies showed that increased expression of
IκB mRNA parallels enhanced NF-κB activity and is used as a marker for increased NFκB activation in neuroinflammatory pain (Ledeboer et al., 2005; Loram et al., 2010;
Yoshikawa et al., 2006). Moreover, studies have indicated the involvement of activated
NF-κB and increased IκB expression in the mediation of neuroinflammatory pain during
microglial activation in the CNS. This amplifies and facilitates pain transmission
(Ledeboer et al., 2005; Loram et al., 2010). Furthermore, enhanced expression of CD11b
represents the severity of microglial activation during neuroinflammation (GonzalezScarano and Baltuch, 1999; Ling and Wong, 1993; Rock et al., 2004).
Given the previous findings, it is expected that reducing microglial and NF-κB
activation in the hippocampus might be of potential therapeutic utility for decreasing
neuroinflammatory pain-like symptoms involving α7 nAChR. Therefore, we
hypothesized that TQS will decrease microglial NF-κB activation in the hippocampus
during antiallodynic and antihyperalgesic effects as reported before (Abbas and Rahman,
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2016). In this study, we have determined the effects of TQS and TEL, an inhibitor of NFkB (Balaji and Ramanathan, 2014; Saavedra, 2012), on IκB mRNA and CD11b mRNA
expression in the hippocampus. In addition, we have examined the effects of TQS on pNF-κB p65 expression in the hippocampus in mice.
3.2. Methods
Animals
Male C57BL/6J mice were obtained from Jackson Laboratory (Bar Harbor, ME,
USA). The animals were housed under standard laboratory conditions as described
previously (see chapter 2, section 2.2).
Drug treatment
TEL was obtained from Tocris Bioscience (Ellisville, MO, USA) and was
reconstituted in normal saline containing 2.6% tween 80 and 2.6% DMSO. The source,
method of reconstitution, and time of administration for other drugs used in this study are
mentioned previously (see chapter 2, section 2.2). TEL was given 5 min before TQS
administration. Neuroinflammatory pain was induced by LPS by the method mentioned
earlier (see chapter 2, section 2.2). The doses for TQS, TEL, and MLA were selected
based on our previous report and others (Abbas and Rahman, 2016; Haraguchi et al.,
2010; Jaggi and Singh, 2011).
Tactile allodynia
Tactile allodynia was measured as described previously (see chapter 2, section
2.2).
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Thermal hyperalgesia
Thermal hyperalgesia was quantified as described earlier (see chapter 2, section
2.2).
RNA isolation and complementary (c)DNA synthesis
Total RNA from hippocampal tissue was isolated and cDNA was synthesized as
mentioned previously with minor modifications (Loram et al., 2010). Briefly, mice were
sacrificed through rapid decapitation six h after LPS administration and their hippocampi
were dissected out. The tissue sections were then frozen on dry ice, and stored in -80oC
refrigerator until further analysis was performed. Hippocampal tissues were then
homogenized in the presence of TRIzol Reagent (Invitrogen, Carlsbad, CA, USA).
Chloroform was added to supernatant and total RNA was precipitated from the aqueous
phase using isopropyl alcohol. The RNA pellet was then reconstituted in RNAse-free
water. The total RNA concentration was determined in a NanoDrop 1000
spectrophotometer (Thermo Scientific, Welmington, DE, USA) at 260 nm. The RNA
samples were then stored at -80°C until further analysis. The RNA quality was measured
with the OD 260/280 ratio that was between 1.9 and 2.1. The RNA integrity was
measured using agarose gel electrophoresis (FisherBiotech electrophoresis system, MiniHorizontal Unit, Fisher Scientific, Waltham, MA USA). Using High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA), the total RNA was
then reverse transcribed into first-strand cDNA in Master Cycler Personal (Eppendorf,
Hauppauge, NY, USA). The reaction mixture comprised of deoxynucleoside
triphosphates Mix, reverse transcription random hexamer primer, reverse transcription
buffer, multiscribe reverse transcriptase, RNase inhibitor, and nuclease free water to a
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total volume of 20 µl. The mixture was then incubated at 25°C for 10 min, at 37°C for 2
h, and at 85°C for 5 min for enzyme deactivation. All cDNA was stored at -80°C until
quantitative real-time polymerase chain reaction (PCR) was performed.
Quantitative real-time PCR
Quantitative real-time PCR was performed as described earlier with minor
modification (Loram et al., 2010). Briefly, cDNA template was used for quantitative realtime PCR reaction. Prime primers were used in this study. Their sequences were obtained
from Integrated DNA Technologies (Coralville, Iowa, USA) and are displayed in Table
1. Amplification of cDNA was carried out using SYBR Select PCR Master Mix Kit
(Applied Biosystems by life technologies, Austin, TX, USA) in StepOnePlus quantitative
real-time PCR system (Applied Biosystems, Carlsbad, CA, USA). The reaction mixture
(20 ul) consisted of cDNA template, SYBR Select PCR Master Mix, 200 nM of prime
primer, nuclease free water. The glyceraldehydes-3-phosphate dehydrogenase (GAPDH)
primer was used as housekeeping gene. No multiscribe reverse transcriptase and No RNA
controls were used as negative control. Reactions were conducted using 96 wells qPCR
plate (Life Technologies, Grand Island, NY, USA). Each sample was used in triplicate
and mean cycle threshold (Ct) was calculated for analysis. Cycling parameters were
given as; 50°C for 2 min once; 95°C for 2 min once; then 95°C for 15 s, 60°C for 30 s,
and 72°C for 1 min and 30 s for 40 cycles ending with a melting curve analysis to control
amplification. The relative expression of each gene was determined using delta-delta Ct
method. The level of the target mRNA was measured relative to GAPDH and presented
as percentage of vehicle control. The expression level of GAPDH was not significantly
different between treatments.
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Table 1: Prime primer sequence for GAPDH, IκB, and CD11b
Gene
GAPDH

Primer sequence (5’-3’)
GTGGAGTCATACTGGAACATGTAG (forward)
AATGGTGAAGGTCGGTGTG (reverse)

IκB

ATGACAGCTACATGGAGTGG (forward)
CCAACCCAGAGAACGAAGAG (reverse)

CD11b

TGTCCAGATTGAAGCCATGA (forward)
CCACAGTTCACACTTCTTTCAG (reverse)

Immunofluorescence assay
Immunofluorescence assay was performed as previously described with minor
modification (Ali et al., 2015). Briefly, mice were sacrificed through rapid decapitation
six h after LPS administration. Their whole brains were then harvested and fixed with 4%
paraformaldehyde for 24 h at room temperature. Mice brains were then cryoprotected
with 30% sucrose for 24 h/until brain sank at 4°C and 14 μm coronal sections were cut
using Leica cryostat and were fixed on superfrost Plus microscope slides (Fisher
Scientific, Pittsburg, PA, USA). Slides were washed with 0.01 molar (M) phosphatebuffered saline (PBS) twice for 5 minute each and were then placed in water bath
maintained at 90°C containing 0.01 M citrate buffer (pH 6.0) for 10 min. Hippocampal
tissue sections were then blocked in 5% normal bovine serum for 2 h at room temperature
having 0.3% triton X-100 in 0.01 M PBS. Tissue sections were incubated with primary
antibody for p-NF-κB p65 (S536, monoclonal, 1:100, Cell Signaling Technology,
Danvers, MA, USA) at 4°C overnight. Tissue sections were then incubated with
secondary antibody labeled with fluorescein isothiocyanate (FITC) (1:50) (Santa Cruz
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Biotechnology, Dallas, TX, USA). The slides were mounted with mounting medium
having 4’,6’-diamidino-2-phenylindole (DAPI) for nuclear staining and prolong anti-fade
reagent (Santa Cruz Biotechnology, Dallas, TX, USA). A negative control lacking
primary antibody and treated with secondary antibody was used. Immunofluorescence
of representative images was examined using a laser scanning confocal microscope
(Olympus Fluoview FV1200). Three tissue sections per animal were used for
immunofluorescence assay while two images were captured per each tissue section and
all were averaged together. The image that was close to average of all was chosen as
representative image. For quantitative analysis, Image J software was used to determine
integrated density.
Statistical analyses
For thermal hyperalgesia, immunofluorescence assay, and quantitative real-time PCR,
data were analyzed by one-way ANOVA followed by Tukey’s post hoc test for multiple
comparisons. For quantitative real-time PCR for MLA and TQS/TEL combination data
for thermal hyperalgesia, Student’s t-test was used. For tactile allodynia, Kruskil-Wallis
test followed by Dunn’s post hoc test for multiple comparisons or Mann-Whitney test for
TQS/TEL combination was applied using GraphPad Prism 5.0 (GraphPad Inc., San
Diego, CA, USA). The difference between treatments was considered as significant at P
< 0.05. All results are expressed as mean ± S.E.M.
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3.3. Results
Effects of TEL on 50% paw withdrawal during von Fey filament test in LPS-induced
neuroinflammatory pain
The effects of TEL on 50% paw withdrawal (tactile allodynia) in von Frey
filament test are shown in Figure 12. Kruskal-wallis test showed that TEL significantly
decreased 50% paw withdrawal threshold (P < 0.0001). Multiple comparisons of means
revealed that LPS (1 mg/kg) significantly (P < 0.001) decreased 50% paw withdrawal
threshold compared to control showing the presence of pain hypersensitivity.
Furthermore, TEL (3 mg/kg) significantly (P < 0.01) enhanced 50% paw withdrawal
threshold compared to LPS treatment group indicating significant antiallodynic effects.
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Figure 12: Lipopolysaccharide (LPS) significantly reduced 50% paw withdrawal
threshold (tactile allodynia) compared to control. Moreover, telmisartan (TEL)
significantly increased 50% paw withdrawal threshold compared to LPS treated group.
Mice were administered TEL (1 or 3 mg/kg, i.p.) 0.5 h before LPS administration.
Control animals received equal volume of vehicle. Paw withdrawal threshold was
determiend using von Frey filaments six h after LPS administration. Data are expressed
as mean + S.E.M. (n = 6-8/group) *P < 0.01; **P < 0.001.
Effects of TEL on latency time during hot plate test in LPS-induced neuroinflammatory
pain
The effects of TEL on latency time (thermal hyperalgesia) in hot plate test are
shown in Figure 13. One way ANOVA showed that TEL significantly altered latency
time in hot plate test (F3,20 = 10.52; P < 0.001). Multiple comparisons of means showed
that LPS (1 mg/kg) significantly (P < 0.001) reduced hot plate latency as compared to
control group indicating significant reduction in response to heat stimulus. Moreover,
TEL (3 mg/kg) significantly (P < 0.01) enhanced hot plate latency compared to LPS
treatment group indicating antihyperalgesic effects of TEL are due to the NF-κB
inactivation.
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Figure 13: Lipopolysaccharide (LPS) significantly reduced latency time (thermal
hyperalgesia) on the hot plate. Moreover, telmisartan (TEL) significantly increased
latency time on hot plate compared to LPS treated group. Mice received TEL (1 or 3
mg/kg, i.p.) 0.5 min before the administration of LPS. Control animals received equal
volume of vehicle. Latency on hot plate was assessed six h after LPS administration Data
are expressed as mean + S.E.M. (n = 6/group) *P < 0.01; **P < 0.001.
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Effects of co-administration of TQS and TEL on 50% paw withdrawal during von Fey
filament test in LPS-induced neuroinflammatory pain
The effects of TQS and TEL co-administration on 50% paw withdrawal (tactile
allodynia) in von Frey filament test are shown in Figure 14. Mann-Whitney test showed
that co-administration of sub maximal dose of TQS and TEL significantly (P < 0.05)
decreased 50% paw withdrawal threshold showing decreased activation of NF-κB in
TQS-induced antiallodynic effects.
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Figure 14: Lipopolysaccharide (LPS) significantly decreased 50% paw withdrawal
threshold (tactile allodynia) compared to control. Furthermore, TQS in combination with
telmisartan (TEL) significantly increased 50% paw withdrawal threshold compared to
TQS treated group. Mice received TEL (1 mg/kg, i.p.) 5 min before TQS (1 mg/kg, i.p.)
administration. LPS was administered 0.5 h after TQS administration. Control animals
received equal volume of vehicle. Paw withdrawal threshold was measured using von
Frey filaments six h after LPS administration. Data are expressed as mean + S.E.M. (n =
6-8/group) *P < 0.05; **P < 0.001.
Effects of co-administration of TQS and TEL on latency time during hot plate test in LPSinduced neuroinflammatory pain
The effects of co-administration of TQS and TEL on latency time (thermal
hyperalgesia) in hot plate test are shown in Figure 15. Student's t-test showed that coadministration of sub maximal dose of TQS and TEL significantly (P < 0.001) enhanced
hot plate latency time showing antihyperalgesic effects of TQS are due to reduced NF-κB
activation.
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Figure 15: Lipopolysaccharide (LPS) significantly decreased latency time (thermal
hyperalgesia) on the hot plate. Moreover, TQS in combination with telmisartan (TEL)
significantly increased latency time on hot plate compared to TQS treated group. Mice
received TEL (1 mg/kg, i.p.) 5 min before TQS (1 mg/kg, i.p.) administration. LPS was
administered 0.5 h after TQS administration. Control animals received equal volume of
vehicle. Latency on hot plate was determined six h after LPS administration. Data are
expressed as mean + S.E.M. (n = 6/group). *P < 0.01; **P < 0.001.
Effects of TQS on IκB mRNA expression in the hippocampus
The effects of TQS on IκB mRNA expression in LPS-induced neuroinflammatory
pain are shown in Figure 16. One way ANOVA showed that TQS significantly reduced
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the expression of IκB mRNA (F3,20 = 23.93; P < 0.0001). Multiple comparisons of means
showed that LPS (1 mg/kg) significantly (P < 0.001) enhanced the expression of IκB
mRNA indicating that LPS-induced neuroinflammatory pain is mediated through NF-κB
activation. Furthermore, TQS (4 mg/kg) significantly (P < 0.001) reduced IκB mRNA
expression in LPS-induced neuroinflammatory pain supporting the hypothesis that TQS
decreased neuroinflammatory pain-like symptoms by decreasing NF-κB activation in the
hippocampus.
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Figure 16: Lipopolysaccharide (LPS) significantly increased inhibitor of kappa B (IκB)
mRNA expression compared to control. Moreover, TQS significantly reduced the
expression of IκB mRNA compared to LPS treated group. Mice were given TQS (1 or 4
mg/kg, i.p.) 0.5 h before LPS administration. Control animals received equal volume of
vehicle. Hippocampi were collected 6 h after LPS administration. The IκB mRNA
expression was measured using quantitative real-time polymerase chain reaction. Data
are expressed as mean + S.E.M. (n = 6/group) *P < 0.001.
Effects of co-administration of TQS and TEL on IκB mRNA expression in the
hippocampus
The effects of co-administration of TQS and TEL on IκB mRNA expression are shown
in Figure 17. Student's t-test showed that co-administration of TQS and TEL significantly
(P < 0.01) reduced IκB mRNA expression which indicates that antiallodynic and
antihyperalgesic effects of TQS are due to reduced activation of NF-κB.
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Figure 17: Lipopolysaccharide (LPS) significantly increased inhibitor of kappa B (IκB)
mRNA expression compared to control. Moreover, telmisartan (TEL) in combination
with TQS significantly reduced the expression of IκB mRNA compared to TQS treated
group. Mice were given TQS (1 mg /kg, i.p.) 0.5 h before LPS administration. TEL (1 mg
/kg, i.p.) was administered 5 min before TQS injection. Control animals received equal
volume of vehicle. Hippocampi were collected 6 h after LPS administration. The IκB
mRNA expression was measured using quantitative real-time polymerase chain reaction.
Data are expressed as mean + S.E.M. (n = 6/group). *P < 0.01; **P < 0.001.
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Effects of MLA on TQS-induced decrease in IκB mRNA expression in the hippocampus
The effects of MLA on TQS-induced decrease in IκB mRNA expression in LPSinduced neuroinflammatory pain are shown in Figure 18. Student's t-test showed that
MLA significantly (P < 0.01) reversed TQS-induced reduction in IκB mRNA expression.
This validated that TQS-induced reduction in IκB mRNA expression is due to α7
nAChR.
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Figure 18: Lipolpolysaccharide (LPS) significantly increased inhibitor of kappa B (IκB)
mRNA expression compared to control. Methyllcaconitine (MLA) significantly
increased IκB mRNA expression compared to TQS treatment group. Mice were
administered TQS (4 mg /kg, i.p.) 0.5 h before LPS administration. The MLA (3 mg /kg,
i.p.) was given 10 min before TQS injection. Control animals received equal volume of
vehicle. Hippocampi were collected 6 h after LPS administration. The IκB mRNA
expression was measured using quantitative real-time polymerase chain reaction. Data
are expressed as mean + S.E.M. (n = 4-6/group). *P < 0.01; **P < 0.0001.
Effects of TQS on CD11b mRNA expression in the hippocampus
The effects of TQS on CD11b mRNA expression in LPS-induced neuroinflammatory
pain are shown in the Figure 19. One way ANOVA showed that TQS significantly
decreased CD11b mRNA expression in LPS-induced neuroinflammatory pain (F3,14 =
10.36; P < 0.001). Multiple comparisons of means showed that LPS significantly (P <
0.01) enhanced the expression of CD11b mRNA indicating the activation of microglia
after LPS administration. Furthermore, TQS (4 mg/kg) significantly (P < 0.01) decreased
CD11b mRNA expression indicative of reduced microglial activation in the
hippocampus.
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Figure 19: Lipopolysaccharide (LPS) significantly increased cluster of differentiation
(CD)11b mRNA expression compared to control. Moreover, TQS significantly reduced
the expression CD11b mRNA compared to LPS treated group. Mice were administered
TQS (1 or 4 mg/kg, i.p.) 0.5 h before LPS administration. Control animals received equal
volume of vehicle. Hippocampi were collected 6 h after LPS administration. The CD11b
mRNA expression was determined using quantitative real-time polymerase chain
reaction. Data are expressed as mean + S.E.M. (n = 4-5/group) *P < 0.01.
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Effects of co-administration of TQS and TEL on CD11b mRNA expression in the
hippocampus
The effects of co-administration of TQS and TEL on CD11b mRNA expression in
LPS-induced neuroinflammatory pain are shown in the Figure 20. Student's t-test
revealed that co-administration of TQS and TEL significantly (P < 0.001) decreased
CD11b mRNA expression indicating reduced microglial activation in the hippocampus.
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Figure 20: Lipopolysaccharide (LPS) significantly increased cluster of differentiation
(CD)11b mRNA expression compared to control. Moreover, TQS in combination with
telmisartan (TEL) significantly reduced the expression CD11b mRNA compared to TQS
treated group. Mice were administered TQS (1 mg /kg, i.p.) 0.5 h before LPS
administration. TEL (1 mg /kg, i.p.) was administered 5 min before TQS injection.
Control animals received equal volume of vehicle. Hippocampi were collected 6 h after
LPS administration. The CD11b mRNA expression was quantified using quantitative
real-time polymerase chain reaction. Data are expressed as mean + S.E.M. (n = 45/group). *P < 0.001.
Effects of MLA on TQS-induced decrease in on CD11b mRNA expression in the
hippocampus
The effects of MLA on TQS-induced decrease in CD11b mRNA expression in LPSinduced neuroinflammatory pain are shown in Figure 21. Student's t-test showed that
MLA significantly (P < 0.001) reversed reduction in the expression of CD11b mRNA.
This validated that TQS-induced reduction in CD11b mRNA is due to α7 nAChR.
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Figure 21: Lipolpolysaccharide (LPS) significantly increased cluster of differentiation
(CD)11b mRNA expression compared to control. Methyllcaconitine (MLA) significantly
increased CD11b mRNA expression compared to TQS treatment group. Mice were
administered TQS (4 mg /kg, i.p.) 0.5 h before LPS administration. The MLA (3 mg /kg,
i.p.) was given 10 min before TQS injection. Control animals received equal volume of
vehicle. Hippocampi were collected 6 h after LPS administration. The CD11b mRNA
expression was quantified using quantitative real-time polymerase chain reaction. Data
are expressed as mean + S.E.M. (n = 4-5/group). *P < 0.001.
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Effects of TQS on the expression of p-NF-κB p65 in CA1 region of hippocampus
The effects of TQS on the expression of p-NF-κB p65 in CA1 are shown in Figure
22. One way ANOVA showed that TQS significantly decreased p-NF-κB p65 expression
in LPS-induced neuroinflammatory pain (F2,10 = 10.95; P < 0.01). Multiple comparisons
of means showed that LPS (1 mg/kg) significantly (P < 0.05) enhanced p-NF-κB p65
expression showing NF-κB activation after LPS administration. Furthermore, TQS (4
mg/kg) significantly (P < 0.01) decreased p-NF-κB p65 expression indicative of reduced
NF-κB activation in CA1 region of hippocampus.
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Figure 22: Lipopolysaccharide (LPS) significantly increased phospho-nuclear factor-κB
(p-NF-κB) p65 expression compared to control in CA1 region of hippocampus. Moreover,
TQS significantly reduced the expression of p-NF-κB p65 compared to LPS treated group.
Mice were administered TQS (4 mg/kg, i.p.) 0.5 h before LPS administration. Control
mice received equal volume of vehicle. Whole brain was collected 6 h after LPS
administration. The p-NF-κB p65 expression was quantified using immunofluorescence
assay. Data are expressed as mean + S.E.M. Representative images show the
immunofluorescence analysis in CA1 in hippocampus. Magnification 20 X, Scale bar =
50 um. (n = 4/group). *P < 0.05; **P < 0.01.
Effects of TQS on the expression of p-NF-κB p65 in DG in hippocampus
The effects of TQS on the expression of p-NF-κB p65 in DG region of the
hippocampus are shown in Figure 23. One way ANOVA showed that TQS significantly
decreased p-NF-κB p65 expression in LPS-induced neuroinflammatory pain (F2,10 =
9.567; P < 0.01). Multiple comparisons of means showed that LPS (1 mg/kg)
significantly enhanced (P < 0.01) p-NF-κB p65 expression indicating the activation of
NF-κB after LPS administration. Furthermore, TQS (4 mg/kg) significantly (P < 0.05)
decreased p-NF-κB p65 expression suggestive of reduced activation of NF-κB in DG
region of hippocampus.

72

Figure 23: Lipopolysaccharide (LPS) significantly increased phospho-nuclear factor-κB
(p-NF-κB) p65 expression compared to control in dentate gyrus (DG) region of
hippocampus. Moreover, TQS significantly reduced the expression of p-NF-κB p65
compared to LPS treated group. Mice were administered TQS (4 mg/kg, i.p.) 0.5 h before
LPS administration. Control mice received equal volume of vehicle. Whole brain was
collected 6 h after LPS administration. The p-NF-κB p65 expression was quantified using
immunofluorescence assay. Data are expressed as mean + S.E.M. Representative images
show the immunofluorescence in DG in hippocampus. Magnification 20 X, Scale bar =
50 um. (n = 5/group) *P < 0.05; **P < 0.01.
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3.4. Discussion
The current study showed that pretreatment of TQS decreased IκB mRNA expression, a
downstream marker the expression of which increases when NF-κB is activated and
reduces when NF-κB becomes inactivated, in the hippocampus. This indicates that TQS
causes NF-κB inactivation in LPS-induced neuroinflammatory pain that is likely linked
with antiallodynic and antihyperalgesic effects in LPS-induced neuroinflammatory pain
reported earlier (Abbas and Rahman, 2016). Moreover, co-administration of TEL, an NFκB inhibitor, and TQS decreased the expression of IκB mRNA and LPS-induced tactile
allodynia and thermal hyperalgesia associated with active NF-κB in LPS-induced
neuroinflammatory pain. TQS also reduced immunoreactivity of p-NF-κB p65 both in DG
and CA1 regions of the hippocampus. Furthermore, TQS decreased LPS-induced
microglial activation due to reduced CD11b mRNA, a microglial activation marker,
expression in the hippocampus. Pretreatment of MLA, an α7 nAChR antagonist,
reversed TQS-induced reduction in the expression of IκB mRNA and CD11b mRNA in
the hippocampus showing the involvement of α7 nAChR. Taken together, these results
indicate that TQS decreases LPS-induced neuroinflammatory pain by decreasing
hippocampal microglial activation due to reduced NF-κB activation involving microglial
α7 nAChR (Figure 24).
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Figure 24: Proposed schematic of TQS effects against neuroinflammatory pain. TQS acts
through microglial α7 nAChR positive allosteric modulatory site in the hippocampus.
This results in reduced NF-κB activation through decreased microglial activation.
Inhibition of NF-κB activity with TQS reduces the expression of IκB mRNA and
neuroinflammatory pain-like symptoms.
The data presented in the current study are in line with the evidence that active
NF-κB in microglial cells is a key mediator in LPS-induced neuroinflammatory pain
model (Abbas and Rahman, 2016). The high level of IκB mRNA, a downstream mediator
that indicates NF-κB activation, in the CNS is associated with development of
neuroinflammatory pain-like symptoms (Loram et al., 2010). Moreover, the NF-κB
activation linked with pain hypersensitivity has been characterized in other models of
pain (Bethea et al., 1998; Ma and Bisby, 1998; Wilms et al., 2003) and is likely involved
in increased pain sensitivity. Intrathecal administration of HIV-1 envelope glycoprotein
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was shown to enhance NF-κB activation in the CNS in inflammatory model of pain
(Milligan et al., 2000). Our findings of TQS effects on pain phenotypes and the downregulation of the NF-κB activity provide credence to the above results and validate a link
between active NF-κB and increased pain sensitivity in LPS-induced neuroinflammatory
pain model in our mice model.
Our results showed that TQS in combination with TEL had synergistic effects on
reduced I-κB mRNA expression and associated tactile allodynia and thermal hperalgesia
indicating the utilization of NF-κB in activated microglial cells during antiallodynic and
antihyperalgesic effects. It is important to note that TEL was found to reduce LPSinduced activation of NF-κB within microglial-like cells (Balaji and Ramanathan, 2014;
Saavedra, 2012). In addition, TEL was shown to have efficacy in neuropathic pain (Jaggi
and Singh, 2011) in animal model.
While TEL is regarded as an inhibitor of NF-kB, it is known to antagonize an
angiotensin II receptor and is indicated in the treatment of hypertension. The drug also
works as a partial agonist at peroxisome proliferator-activated receptor-gamma (PPARγ), a nuclear transcription factor (Haraguchi et al., 2010). Additionally, TEL exerts antiinflammatory actions by reducing the expression of pro-inflammatory genes. These
effects of TEL are mediated due to its PPAR-γ receptor activation property (Bernardo
and Minghetti, 2006; Kapadia et al., 2008). Therefore, TEL-induced antiallodynic or
antihyperalgesic effects are likely due to decreased activation of NF-κB in the
hippocampus linked with PPAR-γ activation in hippocampal microglia. However,
additional studies are required to validate the specific role of PPAR-γ associated with
TEL actions in neuroinflammatory pain model.
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The pretreatment of MLA, an α7 nAChR antagonist, reduced TQS-induced
reduction in the level of I-κB mRNA in the hippocampus confirming the involvement of
α7 nAChRs in the inactivation of NF-κB. To the best of our knowledge, this is the first
finding that showed that occupancy of microglial α7 nAChR positive allosteric
modulatory sites in the hippocampus causes reduction in the activation of NF-κB in
neuroinflammatory pain. We, therefore, propose that microglial NF-κB activation should
be inhibited for the blockade of LPS-induced neuroinflammatory pain.
Previous studies have indicated that neurons in CA1 region of the hippocampus
mediate responses to painful stimuli (Khanna and Sinclair, 1989; Martuscello et al.,
2012). Furthermore, other studies showed that the hippocampal DG and CA1 region play
very important in neural processing of persistent pain (Soleimannejad et al., 2007). Our
findings support the concept that both CA1 and DG are critically involved in the
development and maintenance of painful symptoms. Our results indicated that LPS
enhanced the expression of p-NF-κB p65 in DG and CA1 in microglial cells in pain
hypersensitivity. The TQS caused a significant reduction of p-NF-κB p65 in these regions
indicating that TQS-induced antiallodynic and antihyperalgesic effects are due to reduced
NF-κB activation in DG and CA1. However, additional studies are needed involving
direct microinjection of LPS and/or TQS in the hippocampus.
The fact that enhanced activation of NF-κB in the hippocampus is linked with
increased microglial activation can be measured by increased CD11b mRNA expression
in neuroinflammatory pain. Previously, we showed that TQS reduces the expression of
Iba-1 in the hippocampus indicating the involvement of active microglia in LPS-induced
neuroinflammatory pain (Abbas and Rahman, 2016). Previous studies showed that
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neuroinflammatory pain is connected with neuropathic pain through microglial activation
and other mediators (Ellis and Bennett, 2013; Jha et al., 2012; Zhuo et al., 2011). We
propose that NF-κB positive cells are microglial cells that are highly involved in
inflammatory process and facilitate painful behavior in animal models. It is possible that
activated microglial cells in these regions of the hippocampus hypersensitize the neurons
that mediate increased pain sensitivity. Therefore, antiallodynic and antihyperalgesic
effects of TQS on  nAChR positive allosteric modulatory sites within the hippocampus
are likely due to microglial cells, as LPS-induced enhanced CD11b mRNA expression
was significantly reduced by TQS.
The co-administration of TQS and TEL resulted in decreased LPS-induced
enhanced expression of CD11b mRNA. Pretreatment of MLA reversed TQS-induced
reduction in the expression of CD11b mRNA suggesting activation of α7 nAChR
decreases microglial activation in the hippocampus. Activation of NF-κB within the
microglial cells enhances the expression of proinflammatory cytokines and pain
mediators involving NF-κB-mediated gene expression that plays a critical role in painful
behavior (Ferrini and De Koninck, 2013; Loram et al., 2010; Miwa et al., 1997). These
findings suggest that reduction in micoglial and NF-κB activation in the hippocampus
due to TQS is possibly associated with reduced tactile alloydynia and thermal
hyperalgesia in this neuroinflammatory pain model. However, additional studies are
warranted to determine the role of proinflammatory cytokines and other pain mediators,
including BDNF in LPS-induced neuroinflammatory pain in the hippocampus.
The role for  expression and -targeting ligands in the cholinergic regulation
of inflammation is highly established (de Jonge and Ulloa, 2007), the exact way in which
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this connection is linked is not clearly known (Skok, 2009). Conventional thinking might
presume that ligands such as GTS-21, an  partial agonist that has been shown in
numerous research studies to be an effective regulator of neuroinflammation (Bruchfeld
et al., 2010; Giebelen et al., 2007a, b; Hu et al., 2014; Kageyama-Yahara et al., 2008;
Kox et al., 2009; Pavlov et al., 2007; Rosas-Ballina et al., 2009; Thomsen and Mikkelsen,
2012; van Westerloo et al., 2006; Wongtrakool et al., 2007; Wu et al., 2014; Yue et al.,
2015), regulate neuroinflammation involving receptors' ion channel activity. However,
even with the most effective agonists, under the best of conditions,  nAChR have a
very low possibility of channel activation (Williams et al., 2012) and the critical
screening of  agonists with calcium flux measurement requires that the drugs should be
given with a type II PAM in order to overcome the  nAChR desensitization (Roncarati
et al., 2008a). These findings would support the hypothesis that TQS in our experiments
is working in the presence of endogenous ACh and/or choline to affect microglial
function via channel-mediated calcium signals.
The nAChR in non-neuronal cells, including microglial cells might be processed
differently from those in excitable cells such as neurons (Beckmann and Lips, 2013;
Gahring and Rogers, 2005) and previous studies of  nAChR effects on microglial
signal transduction (Hua et al., 2014; Morioka et al., 2015; Thomsen and Mikkelsen,
2012) fail to show any proof for -mediated ion currents. These observations lend
credence to an alternative hypothesis that  nAChR might work as metabotropic
receptors, modulating signal transduction pathways by the induction of specific nonconducting states associated with the receptor's cellular interactome (Kabbani et al.,
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2013; King et al., 2015; Mulcahy et al., 2015; Paulo et al., 2009) which are due to unique
features of 's intracellular domain (Stokes et al., 2015).
The concept that the activity of  nAChR in reducing neuroinflammatory pain is
independent of ion-channel activation is further validated by the finding that NS6740,
which is primarily a channel desensitizer, is efficacious in numerous pain models (Papke
et al., 2015) as the TQS analog GAT107 (Bagdas et al., 2016) which is a allosteric
agonist and a very effective Type II PAM. It is, therefore, very likely that the effects of
TQS in reducing neuroinflammatory pain are due to the direct induction of specific nonconducting  conformational states arising from the binding of the PAM at allosteric
site and initiating downstream signaling pathway.
An interesting question would be to what extent the activity of ligands at the 
orthosteric sites plays a role in reducing neuroinflammatory pain by PAMs.
Concentrations of ACh in the brain are constantly changing and much of the ACh release
is through volume instead of synaptic transmission (Descarries et al., 1997) so that ACh
could easily reach microglial cells to act in the presence of systemically administered
PAMs. Furthermore, choline, a selective activator of  (Papke et al., 1996) is
ubiquitous in the brain at a concentration of around 10 µM and may rise to much higher
concentrations at inflammation or sites of trauma (Farooqui and Horrocks, 1994; Jope
and Gu, 1991; Klein et al., 1997; Scremin and Jenden, 1991; Tartaglia et al., 2002). In
conclusion, our results indicate that LPS-induced tactile allodynia and thermal
hyperalgesia are mediated by microglial NF-κB activation involving α7 nAChR positive
allosteric modulation.
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Chapter 4: Effects of α7 nAChR PAM on microglial TNF expression and NE level in
the hippocampus
4.1. Introduction
We have observed that TQS reduces painful behavior in animal models involving
reduced NF-κB activation in hippocampus (see chapter 2). Moreover, it has been shown
that increasing TNF in the hippocampus induces neuroinflammatory pain-like symptoms
in animal models (Covey et al., 2000; Ignatowski et al., 1999). A previous study
indicated that sustained high level of TNF exclusively in the hippocampus induces
neuroinflammatory pain-like symptoms (Martuscello et al., 2012). Moreover, i.c.v.
injection of recombinant TNF produces neuroinflammatory pain-like symptoms within
CNS (Covey et al., 2002; Ignatowski et al., 1999; Oka et al., 1996). Thus, increasing TNF
in the hippocampus causes increased pain sensitivity (Shubayev and Myers, 2000). We,
therefore, propose that inhibition of TNF in the hippocampus might elicit reduced painful
symptoms due to increased NE level involving α7 nAChRs and α2 adrenergic receptors.
Previously, it was shown that hippocampus is innervated extensively with presynaptic α2-adrenergic receptors that play very important role in the release of NE
involving TNF (Kiss et al., 1995; Scheinin et al., 1994). For example, in
neuroinflammatory pain-like condition, the release of NE in the hippocampus is reduced
due to elevated level of TNF (Covey et al., 2000; Ignatowski et al., 1999). Taken
together, the above observation suggests that reduction in the release of NE associated
with high level of TNF in the hippocampus results in neuroinflammatory pain-like
symptoms. We, therefore, propose that reducing TNF and increasing NE level within
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hippocampus through microglial α7 nAChRs positive allosteric modulation might be
potential therapeutic strategy for neuroinflammatory pain.
Idazoxan (IDA) (Remko et al., 2006), a selective α2 receptor antagonist, has high
affinity at α2 adrenergic receptor (Walter et al., 1984). The IDA is a potent α2 adrenergic
receptor blocker (Fong et al., 2000). Due to its enhanced lipid solubility (Fong et al.,
2000; Remko et al., 2006), the IDA is expected to cross BBB. The IDA is used to
characterize the involvement of α2 adrenergic receptor.
Previously we have shown that TQS reduced LPS-induces neuroinflammatory
pain due to decreased microglial and NF-κB activation in the hippocampus involving α7
nAChRs. However, the effects of TQS on TNF expression and NE release in the
hippocampus are not investigated in LPS-induced neuroinflammatory pain. Given the
previous reports, it is probable that reducing TNF and NE in the hippocampus could be of
therapeutic utility for reducing neuroinflammatory pain-like symptoms involving α7
nAChR. Therefore, we hypothesized that TQS will reduce painful behavior by reducing
TNF and increasing NE level in the hippocampus. In the present study, we have
determined the effects of TQS on TNF expression and NE release in the hippocampus in
mice. We also determined the effects of TQS on microglial morphology in the
hippocampus.
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4.2. Methods
Animals
Male C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME,
USA). The mice were housed under standard laboratory conditions as mentioned before
(see chapter 2, section 2.2).
Drug treatment
The IDA was purchased from Sigma-Aldrich (St. Louis, MO, USA) and was
dissolved in normal saline (0.9% NaCl). The IDA (2 mg/kg, i.p.) was administered 1 h
prior to measurement of tactile allodynia and thermal hyperalgesia. The source, method
of reconstitution, and time of administration for other drugs used in this study are
described earlier (see chapter 2, section 2.2). Control animals were administered an equal
volume of vehicle. The dose for IDA was selected based previous report (Andurkar et al.,
2012).
Tactile allodynia
Tactile allodynia was measured as described previously (see chapter 2, section
2.2).
Thermal hyperalgesia
Thermal hyperalgesia was quantified as described before (see chapter 2, section
2.2).
RNA isolation and cDNA synthesis
Total RNA was isolated from hippocampal tissue as described previously (see
chapter 3, section 3.2).
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Quantitative real-time PCR
Quantitative real-time PCR was performed as described earlier (see chapter 3,
section 3.2). Primers sequences were obtained from Integrated DNA Technologies
(Coralville, Iowa, USA) and are displayed in Table 2.
Table 2: Prime primer sequence for GAPDH, and TNF
Primer sequence (5’-3’)

Gene
GAPDH

GTGGAGTCATACTGGAACATGTAG (forward)
AATGGTGAAGGTCGGTGTG (reverse)

TNF

TCTTTGAGATCCATGCCGTTG (forward)
AGACCCTCACACTCAGATCA (reverse)

Enzyme-linked immunosorbent assay (ELISA)
Mice were sacrificed six h after LPS administration through rapid decapitation
and their hippocampi were dissected out. Hippocampal tissues were stored at -80oC until
further analysis. Brain tissue samples were then homogenized in tris buffer saline (1X)
containing protease inhibitor mix (complete, Mini, Roche, Indianapolis, IN, USA) and
1% triton X-100. The hippocampal tissue homogenates were then centrifuged at 17000×g
at 4oC for 30 min. The supernatants were collected and stored at −80°C until further
analysis. The hippocampal TNF was measured by ELISA kit (eBioscience), according to
manufacturer’s instructions.
NE assay
The NE assay was carried out as described earlier with minor modification (Roni
and Rahman, 2013). Briefly, mice were sacrificed by rapid decapitation six h after LPS
administration. Their hippocampi were dissected from 1-mm coronal sections using
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Allen Brain Atlas and mouse brain stereotaxic coordinates. The brain tissue samples were
stored at -80°C until further analysis. For NE assay, hippocampi were diluted with 0.1N
perchloric acid to 5 volumes of their weight (1:5 as g/ml); samples were then
homogenized and centrifuged at 14,000 ×g for 30 min at 4 °C. Twenty μl of resulting
supernatant was injected onto a high performance liquid chromatography (HPLC) system
coupled with electrochemical detection unit (ESA Inc., Chelmsford, MA, USA) to
determine NE. The HPLC system comprised of a solvent delivery module, a Coulochem
III detector equipped with a 5011A analytical cell and 5020 guard cell. The potential for
guard cell was set at +350 mV. The gain of the detector was set at 100 nA for both
electrodes (electrode 1: −150 mV, electrode 2: +220 mV). The mobile phase contained 75
mM NaH2PO4, 1.7 mM 1-octane sulfonic acid, 25 μM EDTA, 100 μL/L triethylamine,
100 mL/L of acetonitrile. The pH of mobile phase was adjusted to 3.0 using Ophosphoric acid. The C-18 analytical column (BetaBasic-18 column, 150×3 mm, Thermo
Hypersil-Keystone, PA, USA) was used as stationary phase and the flow rate was
maintained at 0.15 mL/min during NE assay. Data were collected in ESA
chromatography data system (EZ Chrom Elite, Chelmsford, MA, USA). Peak’s area
under the curve and calibration factors based on the standard solutions (1–100 ng/mL)
were used to determine the quantity of NE and the values are expressed as ng/mg weight
of hippocampal tissue.
Immunofluorescence assay
Immunofluorescence assay was performed as described before (see chapter 3,
section 3.2) using primary antibody for TNF (Santa Cruz Biotech, Dallas, Texas, USA)
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and secondary antibody labeled with FITC (1:50) (Santa Cruz Biotechnology, Dallas,
TX, USA).
Immunohistochemistry
Immunohistochemistry was performed as described earlier with some
modification (Silverman et al., 2014). Briefly, mice were sacrificed six after LPS
administration through rapid decapitation. Their brains were then harvested and fixed
with 4% paraformaldehyde (Acros organics, New Jersey, USA) for 24 h. Mice brains
were then cryoprotected at 4oC in 30% sucrose (Sigma-Aldrich, St. Louis, MO, USA) for
24 h/until brain sank. The 40 μm coronal sections were cut using Leica cryostat. Free
floating sections were then placed in water bath maintained at 90oC having boiling
0.01 M citrate buffer (pH 6.0) for 10 min, followed by quenching in 0.3% hydrogen
peroxide (Acros organics, New Jersey, USA) in methanol for 5-10 min. Hippocampal
tissue sections were then blocked in 1.5% normal goat serum (Santa Cruz Biotech,
Dallas, Texas, USA) at room temperature for 1 h. Free floating sections were then
incubated with primary antibody (goat anti-raabit-Iba-1; 2.25:1000, Wako, Osaka, Japan)
at room temperature for 1.5 h. Sections were then incubated in secondary antibody at
room temperature for 30 min (biotinylated goat anti-rabbit; 5:1000, Santa Cruz Biotech,
Dallas, Texas, USA), followed by staining with avidin-biotin complex,
diaminobenzidine, and mounted on superfrost plus microscope slides (Fisher Scientific,
USA). Images were taken at 20X after overnight drying with bright field microscopy. A
negative control omitting the primary antibody was also carried out. Three to four slices
were processed per each animal used. To quantify Iba-1-positive microglial cells across
different treatments, three to four random fields in the hippocampus were taken.
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Quantification of % area occupied by microglial cells was carried out using Image J
software.
Statistical analyses
For NE assay, ELISA, immunofluorescence assay, and quantitative real-time PCR,
data were analyzed by one-way ANOVA followed by Tukey’s post hoc test for multiple
comparisons. For quantitative real-time PCR for MLA and TQS/IDA combination data
for thermal hyperalgesia, Student’s t-test was used. For tactile allodynia, Mann-Whitney
test for TQS/IDA combination was applied using GraphPad Prism 5.0 (GraphPad Inc.,
San Diego, CA, USA). The difference between treatments was considered as significant
at P < 0.05. All results are expressed as mean ± S.E.M.
4.3. Results
Effects of TQS on TNF mRNA expression in the hippocampus
The effects of TQS on TNF mRNA expression are displayed in Figure 25. One
way ANOVA showed that TQS significantly reduced TNF mRNA expression (F3,12 =
23.78; P < 0.0001). Multiple comparisons of means revealed that LPS (1 mg/kg)
significantly (P < 0.001) enhanced TNF mRNA expression suggesting LPS-induced
neuroinflammatory pain is due to enhanced TNF mRNA expression. Furthermore, TQS
(4 mg/kg) significantly (P < 0.01) reduced the expression of TNF mRNA in LPS-induced
neuroinflammatory pain. This supports our hypothesis that TQS decreases
neuroinflammatory pain-like symptoms by reducing the expression of TNF mRNA in the
hippocampus.
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Figure 25: Lipopolysaccharide (LPS) significantly increased tumor necrosis factor
(TNF) mRNA expression compared to control. Moreover, TQS significantly reduced the
expression of TNF mRNA compared to LPS treated group. Animals were administered
TQS (1 or 4 mg/kg, i.p.) 0.5 h before LPS administration. Control animals received equal
volume of vehicle. Hippocampi were collected 6 h after LPS administration. The TNF
mRNA expression was quantified using quantitative real-time polymerase chain reaction.
Data are expressed as mean + S.E.M. (n = 4/group) *P < 0.01; **P < 0.001.

Effects of MLA on TQS-induced decrease in TNF mRNA expression in the hippocampus
The effects of MLA on TQS-induced reduced TNF mRNA expression are displayed in
Figure 26. Student's t-test revealed that MLA significantly (P < 0.01) reversed the TQS-
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induced reduction in the expression of TNF mRNA. This validated our hypothesis that
TQS-mediated reduction in TNF mRNA expression is due to α7 nAChR.

Figure 26: Lipolpolysaccharide (LPS) significantly increased tumor necrosis factor
(TNF) mRNA expression compared to control. Methyllycaconitine (MLA) significantly
increased TNF mRNA expression compared to TQS treatment group. Mice were
administered TQS (4 mg /kg, i.p.) 0.5 h before LPS administration. The MLA (3 mg /kg,
i.p.) was given 10 min before TQS injection. Control animals received equal volume of
vehicle. Hippocampi were collected 6 h after LPS administration. The TNF mRNA
expression was quantified using quantitative real-time polymerase chain reaction. Data
are expressed as mean + S.E.M. (n = 4/group). *P < 0.01; **P < 0.001.
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Effects of TQS on TNF level in the hippocampus
The effects of TQS on TNF expression are displayed in Figure 27. One way ANOVA
revealed that TQS significantly decreased TNF expression (F3,21 = 43.45; P < 0.0001).
Multiple comparisons of means indicated that LPS (1 mg/kg) significantly (P < 0.001)
enhanced TNF expression indicating LPS-induced neuroinflammatory pain is due to
elevated expression of TNF. Moreover, TQS (1 or 4 mg/kg) significantly (P < 0.001)
reduced the expression of TNF in LPS-induced neuroinflammatory pain indicating TQS
decreased neuroinflammatory pain-like symptoms by reducing TNF expression in the
hippocampus.
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Figure 27: Lipopolysaccharide (LPS) significantly increased the expression of tumor
necrosis factor (TNF) compared to control. Moreover, TQS significantly reduced the
expression TNF compared to LPS treated group. Animals received TQS (1 or 4 mg/kg,
i.p.) 0.5 h before LPS administration. Control animals received equal volume of vehicle.
Hippocampi were collected 6 h after LPS administration. The TNF level was quantified
using enzyme-linked immunosorbent assay. Data are expressed as mean + S.E.M. (n = 67/group). *P < 0.001.
Effects of TQS on TNF expression in CA1 region of hippocampus
The effects of TQS on TNF expression in CA1 region of hippocampus are displayed
in Figure 28. One way ANOVA showed that TQS significantly decreased the expression
of TNF in LPS-induced neuroinflammatory pain (F2,15 = 22.52; P < 0.0001). Multiple
comparisons of means showed that LPS (1 mg/kg) significantly (P < 0.001) enhanced the
expression of TNF. Furthermore, TQS (4 mg/kg) significantly (P < 0.001) decreased the
expression TNF in CA1 indicative of reduced TNF level in CA1 region of hippocampus
during antiallodynic and antihyperalgesic effects of TQS.
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Figure 28: Lipopolysaccharide (LPS) significantly increased tumor necrosis factor
(TNF) expression compared to control in CA1 region of hippocampus. Moreover, TQS
significantly reduced the expression of TNF compared to LPS treated group. Mice were
administered TQS (4 mg/kg, i.p.) 0.5 h before LPS administration. Control mice received
equal volume of vehicle. Whole brain was collected 6 h after LPS administration. The
TNF expression was quantified using immunofluorescence assay. Data are expressed as
mean + S.E.M. Representative images show the immunofluorescence in CA1 region in
hippocampus. Magnification 20 X, Scale bar = 50 um. (n = 6/group). *P < 0.001.
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Effects of TQS on TNF expression in DG in hippocampus
The effects of TQS on TNF expression in DG region of hippocampus are displayed in
Figure 29. One way ANOVA indicated that TQS significantly reduced the expression of
TNF in LPS-induced neuroinflammatory pain (F2,15 = 28.55; P < 0.0001). Multiple
comparisons of means showed that LPS (1 mg/kg) significantly (P < 0.001) increased the
expression of TNF. Furthermore, TQS (4 mg/kg) significantly (P < 0.001) reduced TNF
expression suggestive of decreased TNF level in DG region of hippocampus during
antiallodynic and antihyperalgesic effects of TQS.
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Figure 29: Lipopolysaccharide (LPS) significantly increased tumor necrosis factor (TNF)
expression compared to control in dentate grus (DG) region of hippocampus. Moreover,
TQS significantly reduced the expression of TNF compared to LPS treated group. Mice
were administered TQS (4 mg/kg, i.p.) 0.5 h before LPS administration. Control mice
received equal volume of vehicle. Whole brain was collected 6 h after LPS
administration. The TNF expression was quantified using immunofluorescence assay.
Data are expressed as mean + S.E.M. Representative images show the
immunofluorescence in DG in hippocampus. Magnification 20 X, Scale bar = 50 um. (n
= 5-7/group). *P < 0.001.
Effects of IDA on TQS-induced antiallodynic response in von Fey filament test
The effects of IDA on TQS-induced antiallodynia are displayed in Figure 30.
Mann-Whitney test showed that IDA significantly (P < 0.05) decreased 50% paw
withdrawal threshold compared with TQS treated group indicating that reduction in the
level of NE after IDA pretreatment.
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Figure 30: Lipopolysaccharide (LPS) significantly reduced 50% paw withdrawal
threshold (tactile allodynia) compared to control. Moreover, idazoxan (IDA) significantly
decreased 50% paw withdrawal threshold compared to TQS treated group. Mice received
TQS (4 mg/kg, i.p.) 0.5 h before LPS administration. The IDA (2 mg/kg, i.p.) was
administered 1 h before assessment of tactile allodynia. Control animals received equal
volume of vehicle. Latency on hot plate was measured six h after LPS administration.
Data are expressed as mean + S.E.M. (n = 7-8/group). *P < 0.05; **P < 0.01.
Effects of IDA on TQS-induced antihyperalgesia in hot plate test
The effects of IDA on TQS-induced antihyperalgesia are displayed in Figure 31.
Student's t-test showed that IDA significantly (P < 0.05) reduced hot plate latency time
compared to TQS treated group indicating that antihyperalgesic effects of TQS are due to
increased NE release in the hippocampus.
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Figure 31: Lipopolysaccharide (LPS) significantly reduced latency time (thermal
hyperalgesia) compared to control. Moreover, idazoxan (IDA) significantly decreased
latency time compared to TQS treated group. Mice received TQS (4 mg/kg, i.p.) 0.5 h
before LPS administration. IDA (2 mg/kg, i.p.) was administered 1 h before assessment
of hyperalgesia. Control animals received equal volume of vehicle. Latency on hot plate
was measured six h after LPS administration. Data are expressed as mean + S.E.M. (n =
6/group). *P <0.05; **P < 0.01.
Effects of TQS on NE release in the hippocampus
The effects of TQS on NE release are displayed in Figure 32. One way ANOVA
showed that TQS significantly changed NE level in the hippocampus (F3,20 = 5.943; P <
0.01). Multiple comparisons of means showed that LPS (1 mg/kg) significantly (P <
0.05) reduced the level of NE in the hippocampus indicating LPS-induced
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neuroinflammatory pain is due to reduced NE level in the hippocampus. Furthermore,
TQS (4 mg/kg) significantly (P < 0.01) elevated level of NE in LPS-induced
neuroinflammatory pain suggesting that TQS decreased neuroinflammatory pain-like
symptoms by increasing the level of NE in the hippocampus.

Figure 32: Lipopolysaccharide (LPS) significantly reduced norepinephrine (NE) level
compared to control. Moreover, TQS significantly increased the level of NE compared to
LPS treated group. Animals received TQS (1 or 4 mg/kg, i.p.) 0.5 h before LPS
administration. Control animals received equal volume of vehicle. Hippocampi were
collected 6 h after LPS administration. The NE level was measured by HPLC-EC. Data
are expressed as mean + S.E.M. (n = 5-7/group). *P < 0.05; **P < 0.01.
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Effects of IDA on TQS-induced increase NE level in the hippocampus
The effects of IDA on TQS-induced increased level of NE are displayed in Figure
33. Student's t-test showed that IDA significantly (P < 0.05) reduced the elevated level of
NE in the hippocampus. This validated that TQS-mediated elevated level of NE is due to
α2 adrenergic receptor involvement.

Figure 33: Lipopolysaccharide (LPS) significantly reduced norepinephrine (NE)
compared to control. Moreover, idazoxan (IDA) significantly decreased NE compared to
TQS treated group. Mice received TQS (4 mg/kg, i.p.) 0.5 h before LPS administration.
IDA (2 mg/kg, i.p.) was administered 5 h after LPS administration. Control animals
received equal volume of vehicle. Hippocampi were collected 6 h after LPS
administration. The NE level was measured by HPLC-EC. Data are expressed as mean +
S.E.M. (n = 5-7/group). *P < 0.05; **P < 0.01.
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Effects of TQS on microglial cells morphology in the hippocampus
The effects of TQS on microglial cells morphology (microglial activation) are
displayed in Figure 34. One way ANOVA showed that TQS pretreatment significantly
altered microglial activation in the hippocampus (F3,19 = 11.83; P < 0.001). Multiple
comparisons of means showed that LPS (1 mg/kg) significantly (P < 0.001) elevated
microglial activation by increasing microglial morphology in the hippocampus as
compared to control. Furthermore, TQS (4 mg/kg) significantly (P < 0.05) reduced
microglial activation due to reduction in LPS-induced morphological changes in the
hippocampus compared to LPS treated group.
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Figure 34: Lipopolysaccharide (LPS) significantly increased % area occupied by
microglial cells (increased microglial activation) compared to control. Moreover, TQS
significantly reduced % area occupied by microglial cells (reduced microglial activation)
compared to LPS treated group. Animals received TQS (1 or 4 mg/kg, i.p.) 0.5 h before
LPS administration. Control animals received equal volume of vehicle. Whole brain was
collected 6 h after LPS administration. Microglial morphology was visualized using
diaminobenzidine (DAB) immunohistochemistry. Data are expressed as mean + SEM.
Representative Images indicate microglial morphology in the hippocampus (top panel).
Magnification 20 X, Scale bar = 50 um. (n = 5-6/group). *P < 0.05; **P < 0.001.
4.4. Discussion
The present study demonstrates that administration of TQS increased TNF
expression in the hippocampus. Moreover, MLA, an α7 nAChR antagonist, reversed
TQS-induced reduction in the expression of hippocampal TNF indicating the
involvement of α7 nAChR in TQS-mediated antiallodynic and antihyperalgesic effects.
TQS also decreased the immunoreactivity of TNF in CA1 and DG regions of
hippocampus suggesting that TQS effects are due to reduced TNF expression in these
regions of hippocampus. Furthermore, administration of TQS reduced the level of NE in
the hippocampus. TQS at same dose reduced neuroinflammatory pain-like symptoms as
reported previously (Abbas and Rahman, 2016). Pretreatment of IDA, an α2
adrenoceptors antagonist, reversed TQS-mediated antiallodynic and antihyperalgesic
effects and TQS-induced elevated level of hippocampal NE suggestive TQS decreases
neuroinflammatory pain by increasing NE level in the hippocampus. The TQS also
reduced LPS-induced morphological changes in the hippocampus indicating TQS
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decreases neuroinflammatory pain by reducing microglial activation in the hippocampus.
Taken together, our results show that TQS decreases neuroinflammatory pain through
decreased TNF expression and enhanced level of hippocampal NE involving α7 nAChR.
Our data support the notion that TNF plays a vital role in neuroinflammatory
pain-like symptoms. Elevated level of TNF was previously reported in the hippocampus
in neuroinflammatory pain-like symptoms (Covey et al., 2000; Ignatowski et al., 1999;
Spengler et al., 2007; Xie et al., 2006). Previous studies show that increased TNF in the
hippocampus produces pronociceptive effects. For example, a previous study reported
that increasing TNF solely in the hippocampus results in pain hypersensitivity
(Martuscello et al., 2012). Furthermore, i.c.v. injection of TNF causes pain
hypersensitivity (Oka et al., 1996). Moreover, administration of SiRNA against TNF
causes reduction in neuroinflammatory pain-like symptoms in animal models (Gerard et
al., 2015). Furthermore, i.c.v. microinfusion of TNF-antibodies reduces
neuroinflammatory pain-like symptoms (Ignatowski et al., 1999).
Our results show that TQS distinctly reduces TNF expression in the hippocampus.
This showed that TQS-induces antiallodynic and antihyperalgesic effects against
neuroinflammatory pain are due to reduced TNF in the hippocampus. Moreover, MLA
reversed TQS-mediated decrease in the expression of TNF mRNA expression in the
hippocampus indicating reduction in TNF expression is linked with α7 nAChR.
Furthermore, TQS reduced the immunoreactivity of TNF both in DG and CA1 regions of
hippocampus. Therefore, we consider that TQS decreases neuroinflammatory pain by
reducing TNF in these two hippocampal regions. Moreover, LPS did not elevate TNF
expression in the brain stem (results not shown) suggesting TNF increases only in the
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higher brain centers, including hippocampus. One probable reason may be due to high
density of microglial cells in hippocampus as compared to other brain regions (Lawson et
al., 1990) that may result in increased microglial activation as reported previously
(Silverman et al., 2014) and increased TNF expression following LPS administration.
The effects of α7 nAChRs in the reduction of neuroinflammation have been well
documented. However, exact mechanism by which these ligands reduce
neuroinflammation involving α7 nAChRs is not clearly understood. Moreover, earlier
studies showed that microglial α7 nAChRs are metabotropic receptors, it is, therefore
probable that TQS decreases neuroinflammatory pain-like symptoms by reducing the
expression of TNF through downstream signaling mediators involving NF-κB
inactivation and microglial α7 nAChR in the hippocampus.
Previous studies showed that TNF is critically involved in NE release in the
hippocampus. For example, a study showed that NE level decreases in the hippocampus
due to elevated TNF in increased painful conditions. Moreover, NE level increases in the
hippocampus due to reduced expression of TNF. Our results showed that LPS decreases
NE level in pain hypersensitivity. This may be correlated with elevated TNF as described
previously. Furthermore, IDA reversed the TQS-mediated increase in NE release
suggesting α2 adrenoceptors involvement in the release of NE. Taken together these
results indicate that TQS mediate its antiallodynic and antihyperalgesic effects involving
increased release of NE and reduced expression of TNF in the hippocampus.
The mechanism through which the release of NE is controlled in the hippocampus
involves stimulation of α2-adrenoceptors with NE at presynaptic level of adrenergic
neurons (Dixon et al., 1979). Moreover, cytokines and neurotransmitters are signals of
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foremost importance that play very important role in bidirectional communication
between immune systems and neurons thus maintaining homeostasis. The abnormal
production of one or both of these markers greatly affects the signaling associated by the
other marker leading to pathology. For example, a previous study demonstrated that TNF
plays a very critical role in the release of NE from adrenergic neurons. However, the
exact mechanism through which TNF reduces NE release in the hippocampus is not
clearly known.
Previous study indicated that during pain hypersensitivity, hippocampal NE level
is decreased (Covey et al., 2000) due to elevated TNF. This reduction in NE is linked
with dysregulation of G-protein coupling with presynaptic α2-adrenergic receptorassociated with elevated TNF (Ignatowski and Spengler, 1994; Millan, 2002; Romanelli
and Esposito, 2004; Yaksh, 1985). Therefore, an interaction exits between TNF
expression and G-protein coupling with α2-adrenoceptors affecting the release of NE in
the hippocampus. For example, it was shown that elevated expression of TNF remodels
Gi coupling more than Gs with α2-adrenoceptors causing decrease release of NE in
painful conditions (Covey et al., 2000; Ignatowski et al., 1999).
Our results showed that LPS caused increased TNF expression and reduced NE
level suggesting coupling of Gi more than Gs with α2-adrenergic receptors. TQS
pretreatment on the other hand caused in reduction in the expression of TNF and
increased NE level in the hippocampus demonstrating Gs coupling more than Gi with α2adrenoceptors. Amitriptyline, a tricyclic antidepressant, used in the treatment of painful
conditions has been hypothesized to work same mechanism involving decreased release
of TNF and increased release of NE in the hippocampus (Ignatowski et al., 2005).
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However, further studies are warranted involving the measurement of Gi and Gs level of
hippocampal noradrenergic neurons in LPS-induced neuroinflammatory pain. Taken
together our data indicate that TQS decreased neuroinflammatory pain due to reduced
TNF expression and increased NE level in the hippocampus.
The TLR4 is a pattern recognition receptor that binds to LPS and activates
signaling pathway that causes NF-κB and microglial activation (Palsson-McDermott and
O'Neill, 2004; Rivest, 2003). Microglial activation is determined by measurement of
elevated expression of Iba-1 which is restricted to microglia (Abbas and Rahman, 2016).
Furthermore, microglial cells adopt resting phenotype in inactivated state but undergo
rapid activation in response to acute insults. This results in change in their morphological
phenotype characterized by retracted processes, hypertrophy and amoeboid morphology
under strongly pathological conditions (Chen et al., 2012; Tsuda et al., 2005; Watkins
and Maier, 2003; Zielasek and Hartung, 1996). Our results show that TQS-mediated
antiallodynic and antihyperalgesic effects are due to reduced microglial activation as
indicated by reduced morphological changes in the hippocampus.
In conclusion, our results show that LPS-induced tactile allodynia and thermal
hyperalgesia are due to elevated TNF and reduced NE level in the hippocampus.
Moreover, our study demonstrated that microglial α7 nAChR positive allosteric
modulation in the hippocampus is involved in reducing neuroinflammatory pain-like
symptoms involving decreased TNF expression and increased NE level. Overall, we
propose that reduction in TNF expression and elevated level of NE in the hippocampal is
a critical and attractive therapeutic approach for the clinical utility of neuroinflammatory
pain.
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Chapter 5: Effects of α7 nAChR PAM on microglial BDNF expression in the
hippocampus
5.1. Introduction
We have found in chapter 3 that activation of microglial α7 nAChR results in
reduced NF-κB activation in neuroinflammatory pain. The active NF-κB was shown to
increase BDNF expression from microglial cells (Ji and Suter, 2007). The BDNF has
been reported to be distributed in whole brain with highest level in the hippocampus
(Ernfors et al., 1990). Unlike proinflammatory cytokines, BDNF is not regarded as
inflammatory mediator. However, it plays very important role in the development and
maintenance of neuroinflammatory pain (Coull et al., 2005; Groth and Aanonsen, 2002;
Mannion et al., 1999; Pezet and Malcangio, 2004). The levels of BDNF proteins and
mRNA are increased after neuroinflammation (Mannion et al., 1999). Moreover, LPS is
known to increase the expression of BDNF from microglial cells (Gomes et al., 2013;
Miwa et al., 1997; Tomaz et al., 2014).
The BDNF was found to induce pain hypersensitivity at 4 h after administration
(Guo et al., 2006). The neuroinflammatory pain-like symptoms are decreased by
preventing the release of BDNF from microglia (Coull et al., 2005). Moreover,
microinjection of BDNF in CNS causes increased pain behavior in animal models (Zhou
et al., 2000). The BDNF mediates its effects through TrkB and subsequent activation
signaling cascade(Huang and Reichardt, 2003). The neuroinflammatory pain-like
symptoms are decreased by blocking the signaling between BDNF and TrkB (Coull et al.,
2005). Moreover, supraspinal BDNF-TrkB signaling cascade favors pain facilitation
(Guo et al., 2006). Therefore, BDNF-TrkB signaling pathway represents novel
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mechanism for pain facilitation in LPS-induced neuroinflammatory pain model and
blocking this microglia-neuron signaling pathway might be novel strategy for the
treatment of neuroinflammatory pain.
We have previously reported that TQS, decreases neuroinflammatory pain due to
reduced microglial and NF-κB activation in the hippocampus. However, the effects of α7
nAChR PAMs on BDNF expression in the hippocampus are not known yet. We,
therefore, hypothesized that targeting microglial BDNF within hippocampus via α7
nAChRs PAM will have potential therapeutic ability against neuroinflammatory pain.
The ANA-12 is a selective, potent, and noncompetitive TrkB antagonist (Cazorla
et al., 2011). It has been shown to cross BBB after systemic administration. The active
concentration of ANA-12 was detected in the brain as soon as 30 minutes and remain
upto 6 hours (Cazorla et al., 2011). The ANA-12 is used to examine the role of BDNF at
TrkB (Zhang et al., 2015).
As indicated in chapter 3, the CA1 and DG regions of the hippocampus are
critically involved in pain production and maintenance. These regions of the
hippocampus are densely populated with microglial cells compared with most of other
brain regions indicating potential role of microglial cells in these regions in
neuroinflammatory pain involving BDNF. We, therefore, hypothesized that TQS will
reduce microglial BDNF expression in the hippocampus during antiallodynic and
antihyperalgesic effects as reported previously. In current study, we have determined the
effects of TQS on BDNF expression in the hippocampus. In addition, we have examined
the effects of TQS on Iba-1 expression in the hippocampus in mice.
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5.2. Methods
Animals
Male C57BL/6J mice were obtained from Jackson Laboratory (Bar Harbor, ME,
USA). The mice were housed four in each cage under standard laboratory conditions as
described before (see chapter 2, section 2.2).
Induction of tactile allodynia and thermal hyperalgesia
Tactile allodynia and thermal hyperalgesia were induced as mentioned earlier (see
chapter 2, section 2.2). ANA-12 (0.25 or 0.5 mg/kg) was reconstituted in normal saline
having 0.5% tween 80 and 3.5% DMSO and was given 10 min before TQS injection.
Control animals received an equal volume of vehicle. The source, method of
reconstitution, and time of administration for other drugs used in current study mentioned
earlier (see chapter 2, section 2.2). The doses for TQS, MLA, and ANA-12 were selected
based our previous report and others (Abbas and Rahman, 2016; Callahan et al., 2013;
Zhang et al., 2015).
Tactile allodynia
Tactile allodynia was measured as described previously (see chapter 2, section
2.2).
Thermal hyperalgesia
Thermal hyperalgesia was quantified as described before (see chapter 2, section
2.2).
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RNA isolation and cDNA synthesis
Total RNA was isolated from hippocampal tissue as described earlier (see chapter
3, section 3.2).
Quantitative real-time PCR
Quantitative real-time PCR was performed as mentioned before (see chapter 3,
section 3.2). Primers sequences were obtained from Integrated DNA Technologies
(Coralville, Iowa, USA) and are displayed in Table 3.
Table 3: Prime primer sequence for GAPDH, and BDNF
Primer sequence (5’-3’)

Gene
GAPDH

GTGGAGTCATACTGGAACATGTAG (forward)
AATGGTGAAGGTCGGTGTG (reverse)

BDNF

GCAACCGAAGTATGAAATAACCA (forward)
GTTTATCACCAGGATCTAGCCA (reverse)

Western blot analysis
Western blot analysis was carried out as described in earlier (see chapter 2,
section 2.2) with minor modification. Briefly, mice were sacrificed six h after LPS
administration and their hippocampi was dissected out. The brain tissue samples were
homogenized in RIPA buffer containing Dulbecco’s Phosphate-buffered saline (pH 7.4),
0.1% sodium dodecyl sulfate, 1% Igepal CA-630, and protease inhibitor mix (complete,
Mini, Roche, Indianapolis, IN, USA). Equal amounts of protein (50 μg) were loaded onto
12% gels for sodium dodecyl sulfate polyacrylamide gel electrophoresis. Separated
proteins were transferred onto immobilon-P transfer membrane (EMD Millipore
Corporation, MA, USA) at 40 volt overnight at 4°C. Membranes were then blocked on a
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gyro-rocker with 5% nonfat dry milk in Tris-buffered saline/0.1% tween-20 for 50 min,
and then incubated overnight at 4°C with primary antibodies for BDNF (H-117, 1:300,
rabbit polyclonal, Santa Cruz Biotech, USA), and subsequently with appropriate
secondary antibody. The β-tubulin (E7-S, 1:5,000, mouse monoclonal, University of
Iowa, USA) was used as loading control.
Immunofluorescence assay
Immunofluorescence was carried out as mentioned before (chapter 3, see section
3.2) with minor modification. Briefly, primary antibody for BDNF (H-117, 1:300, rabbit
polyclonal, Santa Cruz Biotech, USA) and secondary antibody labeled with FITC (1:50)
(Santa Cruz Biotechnology, Dallas, TX, USA) were used. Images were captured using a
laser scanning confocal microscope (Olympus Fluoview FV1200).
Statistical analyses
For thermal hyperalgesia, Western blot analysis, immunofluorescence assay, and
quantitative real-time PCR, data were analyzed by one-way ANOVA followed by
Tukey’s post hoc test for multiple comparisons. For quantitative real-time PCR for MLA
and TQS/ANA-12 combination data for thermal hyperalgesia, Student’s t-test was used.
For tactile allodynia, Kruskil-Wallis test followed by Dunn’s post hoc test for multiple
comparisons or Mann-Whitney test for TQS/ANA-12 combination was applied using
GraphPad Prism 5.0 (GraphPad Inc., San Diego, CA, USA). The difference between
treatments was considered as significant at P < 0.05. All results are expressed as mean ±
S.E.M.
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5.3. Results
Effects of ANA-12 on 50% paw withdrawal in von Fey filament test in LPS-induced
neuroinflammatory pain
The effects of ANA-12 on 50% paw withdrawal (tactile allodynia) in von Frey
filament test are shown in Figure 35. Kruskal-wallis test showed that ANA-12
significantly decreased 50% paw withdrawal threshold (F3,21 = 26.67; P < 0.0001).
Multiple comparisons of means revealed that LPS (1 mg/kg) significantly (P < 0.001)
decreased 50% paw withdrawal threshold compared to control showing the presence of
pain hypersensitivity. Furthermore, ANA-12 (0.5 mg/kg) significantly (P < 0.01)
enhanced 50% paw withdrawal threshold compared to LPS treatment group indicating
antiallodynic effects of ANA-12 are due to the blockade of BDNF effects at TrkB.
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Figure 35: Lipopolysaccharide (LPS) significantly decreased 50% paw withdrawal
threshold (tactile allodynia) compared to control. Moreover, ANA-12 significantly
increased 50% paw withdrawal threshold compared to LPS treated group. Mice received
ANA-12 (0.25 or 0.5 mg/kg, i.p.) 30 min before LPS administration. Control animals
received equal volume of vehicle. Paw withdrawal threshold was assessed using von Frey
filaments six h after LPS administration. Data are expressed as mean + S.E.M. (n = 58/group). *P < 0.01, **P < 0.001.
Effects of ANA-12 on latency time in hot plate test in LPS-induced neuroinflammatory
pain
The effects of ANA-12 on latency time (thermal hyperalgesia) in hot plate test are
shown in Figure 36. One way ANOVA showed that ANA-12 significantly altered latency
time in hot plate test (F3,19 = 8.774; P < 0.001). Multiple comparisons of means showed
that LPS (1 mg/kg) significantly (P < 0.001) reduced hot plate latency as compared to
control group indicating significant reduction in hot plate latency time. Moreover, ANA12 (0.5 mg/kg) significantly (P < 0.05) enhanced hot plate latency compared to LPS
treatment group indicating antihyperalgesic effects of ANA-12 are due to the blockade of
BDNF effects at TrkB.
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Figure 36: Lipopolysaccharide (LPS) significantly decreased latency time (thermal
hyperalgesia) on the hot plate. Moreover, ANA-12 significantly increased latency time on
hot plate compared to LPS treated group. Mice received ANA-12 (0.25 or 0.5 mg/kg, i.p.)
30 min before LPS administration. Control animals received equal volume of vehicle.
Latency on hot plate was measured six h after LPS administration. Data are expressed as
mean + S.E.M. (n = 5-6/group).*P < 0.05; **P < 0.001.
Effects of co-administration of TQS and ANA-12 on 50% paw withdrawal threshold in
von Fey filament test in LPS-induced neuroinflammatory pain
The effects of co-administration of TQS and ANA-12 on 50% paw withdrawal
threshold (tactile allodynia) are displayed in Figure 37. Mann-Whitney test showed that
co-administration of TQS and ANA-12 significantly (P < 0.05) decreased 50% paw
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withdrawal threshold indicating reduction in the expression of BDNF during TQSmediated antiallodynic response.

Figure 37: Lipopolysaccharide (LPS) significantly decreased 50% paw withdrawal
threshold (tactile allodynia) compared to control. Furthermore, TQS in combination with
ANA-12 significantly increased 50% paw withdrawal threshold compared to TQS treated
group. Mice received ANA-12 (0.25 mg/kg, i.p.) 10 minutes before TQS (1 mg/kg, i.p.)
injection. The TQS was given 30 minutes before LPS administration. Control animals
received equal volume of vehicle. Paw withdrawal threshold was assessed using von Frey
filaments six h after LPS administration. Data are expressed as mean + S.E.M. (n = 5-8
group). *P < 0.05, **P < 0.001.
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Effects of co-administration of TQS and ANA-12 on latency time in hot plate test in LPSinduced neuroinflammatory pain
The effects of co-administration of TQS and ANA-12 on latency time (thermal
hyperalgesia) are displayed in Figure 38. Student's t-test revealed that co-administration
of TQS and ANA-12 significantly (P < 0.0001) elevated latency time in hot plate test
indicating antihyperalgesic effects of TQS are mediated through reduced BDNF
expression.

Figure 38: Lipopolysaccharide (LPS) significantly decreased latency time (thermal
hyperalgesia) on the hot plate. Moreover, TQS in combination with ANA-12 significantly
increased latency time on hot plate compared to TQS treated group. Mice received ANA12 (0.25 mg/kg, i.p.) 10 minutes before TQS (1 mg/kg, i.p.) injection. TQS was given 0.5
h before LPS administration. Control animals received equal volume of vehicle. Latency
on hot plate was measured six h after LPS administration. Data are expressed as mean +
S.E.M. (n = 5-6/group). *P < 0.01; **P < 0.001.
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Effects of TQS on BDNF mRNA expression in the hippocampus
The effects of TQS on the expression of BDNF mRNA are displayed in Figure 39.
One way ANOVA showed that TQS significantly reduced the expression of BDNF
mRNA (F3,13 = 8.128; P < 0.01). Multiple comparisons of means showed that LPS (1
mg/kg) significantly (P < 0.05) elevated the expression of BDNF mRNA suggesting
LPS-induced neuroinflammatory pain is due to increased expression of BDNF.
Furthermore, TQS (1 or 4 mg/kg) significantly (P < 0.01) reduced the expression of
BDNF mRNA in LPS-induced neuroinflammatory pain supporting the hypothesis that
TQS reduced neuroinflammatory pain-like symptoms by reducing BDNF expression in
the hippocampus.
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Figure 39: Lipopolysaccharide (LPS) significantly increased brain-derived neurotrophic
factor (BDNF) mRNA expression compared to control. Moreover, TQS significantly
reduced the expression of BDNF mRNA compared to LPS treated group. Animals were
administered TQS (1 or 4 mg/kg, i.p.) 0.5 h before LPS administration. Control animals
received equal volume of vehicle. Hippocampi were collected 6 h after LPS
administration. The BDNF mRNA expression was quantified using quantitative real-time
polymerase chain reaction. Data are expressed as mean + S.E.M. (n = 4-5/group). *P <
0.05, **P < 0.01.

Effects of MLA on TQS-induced decrease in BDNF mRNA expression in the hippocampus
The effects of MLA on TQS-induced decrease in BDNF mRNA expression are
displayed in Figure 40. Student's t-test indicated that MLA significantly (P < 0.01)
reversed TQS-induced decrease in BDNF mRNA expression. This confirmed that TQSinduced decrease in BDNF mRNA is mediated through α7 nAChR.
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Figure 40: Lipolpolysaccharide (LPS) significantly increased brain-derived neurotrophic
factor (BDNF) mRNA expression compared to control. Methyllycaconitine (MLA)
significantly increased BDNF mRNA expression compared to TQS treatment group.
Mice were administered TQS (4 mg /kg, i.p.) 0.5 h before LPS administration. The MLA
(3 mg /kg, i.p.) was given 10 min before TQS injection. Control animals received equal
volume of vehicle. Hippocampi were collected 6 h after LPS administration. The BDNF
mRNA expression was quantified using quantitative real-time polymerase chain reaction.
Data are expressed as mean + S.E.M. (n = 4-5/group). *P < 0.05; **P < 0.01.
Effects of TQS on BDNF expression in the hippocampus
The effects of TQS on BDNF expression are displayed in Figure 41. One way
ANOVA showed that TQS significantly reduced the expression of BDNF (F3,12 = 5.204;
P < 0.05). Multiple comparisons of means showed that LPS (1 mg/kg) significantly (P <
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0.05) elevated BDNF expression suggesting LPS-induced neuroinflammatory pain is due
to increased BDNF expression in the hippocampus. Furthermore, TQS (4 mg/kg)
significantly (P < 0.05) reduced BDNF expression in LPS-induced neuroinflammatory
pain supporting our hypothesis that TQS decreased neuroinflammatory pain-like
symptoms by decreasing BDNF expression in the hippocampus.

Figure 41: Lipopolysaccharide (LPS) significantly increased brain-derived neurotrophic
factor (BDNF) expression compared to control. Moreover, TQS significantly reduced the
expression of BDNF compared to LPS treated group. Animals were administered TQS (1
or 4 mg/kg, i.p.) 0.5 h before LPS administration. Control animals received equal volume
of vehicle. Hippocampi were collected 6 h after LPS administration. Representative
Western blots for BDNF expression from hippocampus (top panel). Data are expressed as
mean + S.E.M. (n = 4/group) *P < 0.05.
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Effects of TQS on BDNF expression in CA1 in hippocampus
The effects of TQS on BDNF expression in CA1 region of the hippocampus are
displayed in Figure 42. One way ANOVA showed that TQS significantly decreased
BDNF expression in LPS-induced neuroinflammatory pain (F2,11 = 22.39; P < 0.001).
Multiple comparisons of means showed that LPS (1 mg/kg) significantly (P < 0.001)
elevated the expression of BDNF. Furthermore, TQS (4 mg/kg) significantly (P < 0.001)
decreased BDNF expression in CA1 region of hippocampus.
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Figure 42: Lipopolysaccharide (LPS) significantly increased brain-derived neurotrophic
factor (BDNF) expression in CA1 region of hippocampus compared to control.
Moreover, TQS significantly reduced the expression of BDNF compared to LPS treated
group. Mice were administered TQS (4 mg/kg, i.p.) 0.5 h before LPS administration.
Control mice received equal volume of vehicle. Whole brain was collected 6 h after LPS
administration. The BDNF expression was quantified using immunofluorescence assay.
Data are expressed as mean + S.E.M. Representative images show the
immunofluorescence in CA1 in hippocampus. Magnification 20 X, Scale bar = 50 um. (n
= 4-5/group). *P < 0.001.
Effects of TQS on BDNF expression in DG in hippocampus
The effects of TQS on BDNF expression in DG region of the hippocampus are
displayed in Figure 43. One way ANOVA indicated that TQS significantly decreased the
expression of BDNF in LPS-induced neuroinflammatory pain (F2,12 = 41.70; P < 0.0001).
Multiple comparisons of means showed that LPS (1 mg/kg) significantly (P < 0.001)
elevated the expression of BDNF. Furthermore, TQS (4 mg/kg) significantly (P < 0.001)
decreased BDNF expression in DG region of hippocampus.
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Figure 43: Lipopolysaccharide (LPS) significantly increased brain-derived neurotrophic
factor (BDNF) expression in dentate gyrus (DG) of hippocampus compared to control.
Moreover, TQS significantly reduced the expression of BDNF compared to LPS treated
group. Mice were administered TQS (4 mg/kg, i.p.) 0.5 h before LPS administration.
Control mice received equal volume of vehicle. Whole brain was collected 6 h after LPS
administration. The BDNF expression was quantified using immunofluorescence assay.
Data are expressed as mean + S.E.M. Representative images show the
immunofluorescence in DG in hippocampus. Magnification 20 X, Scale bar = 50 um. (n
= 5/group). *P < 0.001.
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Effects of TQS on Iba-1 expression in CA1 in hippocampus
The effects of TQS on Iba-1 expression in CA1 region of the hippocampus are
displayed in Figure 44. One way ANOVA showed that TQS significantly affected Iba-1
expression in LPS-induced neuroinflammatory pain (F2,9 = 18.34; P < 0.001). Multiple
comparisons of means showed that LPS (1 mg/kg) significantly (P < 0.01) elevated the
expression of Iba-1. Furthermore, TQS (4 mg/kg) significantly (P < 0.01) decreased Iba1 expression in CA1 region of hippocampus.
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Figure 44: Lipopolysaccharide (LPS) significantly increased ionized-calcium binding
adaptor molecule 1 (Iba-1) expression compared to control in CA1 region of
hippocampus. Moreover, TQS significantly reduced the expression of Iba-1 compared to
LPS treated group. Mice were administered TQS (4 mg/kg, i.p.) 0.5 h before LPS
administration. Control mice received equal volume of vehicle. Whole brain was
collected 6 h after LPS administration. The Iba-1 expression was quantified using
immunofluorescence assay. Data are expressed as mean + S.E.M. Representative images
show the immunofluorescence in CA1 in hippocampus. Magnification 20 X, Scale bar =
50 um. (n = 4/group) *P < 0.01.
Effects of TQS on Iba-1 expression in DG in hippocampus
The effects of TQS on Iba-1 expression in DG region of the hippocampus are
displayed in Figure 45. One way ANOVA indicated that TQS significantly decreased the
expression of Iba-1 in LPS-induced neuroinflammatory pain (F2,11 = 14.93; P < 0.001).
Multiple comparisons of means showed that LPS (1 mg/kg) significantly (P < 0.001)
elevated the expression of Iba-1. Furthermore, TQS (4 mg/kg) significantly (P < 0.05)
decreased Iba-1 expression in DG region of hippocampus.
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Figure 45: Lipopolysaccharide (LPS) significantly increased ionized calcium-binding
adaptor molecule 1(Iba-1) expression compared to control in dentate gyrus (DG) region
of hippocampus. Moreover, TQS significantly reduced the expression of Iba-1 compared
to LPS treated group. Mice were administered TQS (4 mg/kg, i.p.) 0.5 h before LPS
administration. Control mice received equal volume of vehicle. Whole brain was
collected 6 h after LPS administration. The Iba-1 expression was quantified using
immunofluorescence assay. Data are expressed as mean + S.E.M. Representative images
show the immunofluorescence in DG in hippocampus. Magnification 20 X, Scale bar =
50 um. (n = 4-5/group) *P < 0.05; **P < 0.001.
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5.4. Discussion
The present study demonstrated that administration of TQS decreased the
expression of BDNF in the hippocampus. TQS at same dose decreased
neuroinflammatory pain-like symptoms as reported before (Abbas and Rahman, 2016). In
support of this concept, co-administration of sub maximal dose of both TQS and ANA-12
produced antiallodynic and antihyperalgesic effects. This validated that TQS-mediated
antiallodynic and antihyperalgesic effects of TQS are due to decreased BDNF expression
in the hippocampus. Furthermore, TQS-induced decrease in the expression of BDNF
mRNA was reversed by MLA confirming the involvement of α7 nAChR in TQS effects.
TQS also decreased the immunoreactivity of Iba-1, a microglial activation marker, in
CA1 and DG regions of hippocampus showing TQS decreases neuroinflammatory pain
through reducing microglial activation in the hippocampus. Taken together, these data
strongly indicate that reduced expression of microglial BDNF is critically involved in the
mediation of TQS-induced antiallodynic and antihyperalgesic effects involving α7
nAChR in our mouse model for neuroinflammatory pain.
Our data are consistent with this view that microglial BDNF is a key mediator in
LPS-induced neuroinflammatory pain model. For example, BDNF induces painful
response in neuroinflammatory pain conditions (Groth and Aanonsen, 2002; Trang et al.,
2011). A pervious study indicated that the expression of BDNF is significantly elevated
in animal model of spinal nerve ligation (Li et al., 2006) associated with microglial
activation (Coull et al., 2005; Cragg et al., 2010). Microinjection of BDNF into spinal
cord causes increased pain behavior in animal models (Zhou et al., 2000). Furthermore,
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intraplantar injection of BDNF also causes in increased pain like symptoms in animal
models (Shu and Mendell, 1999).
The BDNF is proposed to enhance pain behavior due to increased activation of
NKCC1 and reduced KKC2 expression (Price et al., 2005). Anti-BDNF antibodies have
been shown to reduce pain behavior in animal models (Quintao et al., 2008). Moreover,
administration of TrkB antibody also decreased the development of painful symptoms
(Yajima et al., 2002). Additionally, sequestering BDNF using TrkB-Fc fusion protein
also decreased the development of pain symptoms. Furthermore, Knockdown of BDNF
using siRNA decreases the development of pain behavior (Coull et al., 2005). Therefore,
eliminating BDNF reduces neuroinflammatory pain in animal models (Zhao et al., 2006).
Our observations, of coincident effects of TQS on the pain behavior and the downregulation of the BDNF pathway lend credence to the above findings and validate a link
between enhanced BDNF expression and pain hypersensitivity in LPS-induced
neuroinflammatory pain model in mice. It is noteworthy to mention that, LPS failed to
increase BDNF expression in the brain stem (data not shown), validating the BDNF
expression in specific brain region (i.e. hippocampus) in neuroinflammatory pain.
Together, these findings indicate the possibility that BDNF might be required for the
development of inflammatory pain in animal models.
Our findings showed that co-administration of TQS with ANA-12 had synergistic
effects in decreasing neuroinflammatory pain-like symptoms suggesting the involvement
of BDNF-mediated signaling in microglial cells during antiallodynic and antihyperalgesic
effects. Moreover, the pretreatment of MLA, an α7 nAChR antagonist, reversed TQSinduced decrease in the expression of BDNF mRNA in the hippocampus validating the
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involvement of α7 nAChRs. To the best of our knowledge, this is the first report which
shows that occupancy of microglial α7 nAChR positive allosteric modulatory site in the
hippocampus results in reduced BDNF expression in neuroinflammatory pain. We
propose that microglial BDNF might need to be inhibited for the blockade of LPSinduced neuroinflammatory pain.
Our results showed that LPS enhanced BDNF expression in DG and CA1 regions,
hippocampal regions involved in pain processing and perception, in LPS-induced painful
conditions. TQS, however, resulted in marked reduction in the expression of BDNF in
these both regions indicating that TQS decreases painful behavior via reduced BDNF
expression in DG and CA1. However, further studies are needed involving direct
microinjection of LPS and/or TQS in the hippocampus and to examine change in BDNF
expression directly in the hippocampus.
The fact is that enhanced expression of BDNF in CA1 and DG regions of the
hippocampus is associated with microglial activation can be inferred by increased
expression of Iba-1, a microglial activation marker, in neuroinflammatory pain. We
propose that BDNF positive cells are microglial cells that are highly implicated pain
hypersensitivity. We would hypothesize that activated microglial cells in these both
regions of the hippocampus hypersensitize the neuronal elements through downstream
signaling mediating painful behavior. It is, therefore, possible that key effects of TQS on
microglial  nAChR positive allosteric modulatory sites within CA1 and DG regions of
the hippocampus are due to microglial cells, as LPS-induced increased immunoreactivity
of Iba-1 was significantly attenuated by TQS. However, the exact mechanism through
which microglial BDNF affects painful behavior by hypersensitizing neurons is not
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clearly known. Previous studies have shown that NKCC1 and KCC2 might be involved.
BDNF plays central role in the regulation of NKCC1 and KCC2 involving TrkB pathway
(Rivera et al., 2002; Rivera et al., 2004). Both NKCC1 and KCC2 are predominately
expressed on neurons and plays very important role in maintaining neuronal chloride
homeostasis. Moreover, inflammation has been shown to increase NKCC1 activity and
decreases KCC2 expression resulting in increased pain sensitivity due to GABAmediated dis-inhibition. Therefore, further studies are warranted to examine the
involvement of NKCC1 and KCC2 in LPS-induced neuroinflammatory pain in the
hippocampus.
In conclusion, our results demonstrate that LPS-induced tactile allodynia and
thermal hyperalgesia involve increased expression of microglial BDNF and associated
pathway involving microglial α7 nAChR. Moreover, our study has show that TQS
decreases neuroinflammatory pain due to reduced BDNF expression in the hippocampus.
Overall, we propose that inhibition of microglial BDNF expression is a critical and novel
therapeutic target for the clinical utility of neuroinflammatory pain.
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Chapter 6: Effects of α7 nAChR PAM on NKCC1 and KCC2 expression and NKCC1
activation in the hippocampus
6.1. Introduction
As reported in chapter 5, the BDNF released from activated microglia is critically
involved in the expression of NKCC1 and KCC2 and NKCC1 activation (Benarroch,
2010; Coull et al., 2005; De Koninck, 2007; Ellis and Bennett, 2013). In the CNS, both
NKCC1 and KCC2 are major players in maintaining intracellular regulation of Cl- (Kaila,
1994). The NKCC1 is involved for the movement of Cl- into the cell (Haas, 1994; Plotkin
et al., 1997) while KKC2 causes Cl- movement out of cell thus maintaining neuronal
homeostasis (Delpire and Mount, 2002; Payne et al., 1996; Plotkin et al., 1997). The
activity of both of these cation-chloride co-transporters is involved in control and
regulation of neuronal excitability. The function of NKCC1 is regulated by NKCC1
phosphorylation (the active form of NKCC1) and show a mechanism for increased
activity of this transporter (Darman and Forbush, 2002).
Previous studies have indicated that NKCC1 and KCC2 play a very critical role in
the generation and maintenance of neuroinflammatory painful conditions and their
expression is altered in neuroinflammatory pain (Coull et al., 2003; Galan and Cervero,
2005; Nomura et al., 2006). For example the increased gene expression for NKCC1
results in painful responses while NKCC1 knock-out mice tolerate heat stimulus (Laird et
al., 2004; Sung et al., 2000). Moreover, acute inflammatory pain was reported to be
associated with increased activity of NKCC1 and reduced KKC2 expression (Galan and
Cervero, 2005; Lee et al., 2014; Nomura et al., 2006).Taken together, these studies show
that increased activity of NKCC1 and reduced KCC2 activity might be involved in pain
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hypersensitivity and blocking NKCC1 expression and activation and increasing KCC2
expression might be a novel target for neuroinflammatory pain treatment.
Bumetanide (BU) is a loop diuretic used for the treatment of edema due to
hepatic, renal disease, and congestive heart failure (Hughes and Lustman, 1990; Ward
and Heel, 1984). The Bu possesses 500-fold greater affinity for NKCC1 (Ki value of
approximately 0.1 mM) than for KCC2 (Ki of approximately 25–50 mM). Therefore, Bu
is relatively specific and potent inhibitor of NKCC1 and is an ideal tool to examine the
role of NKKC1 in the hippocampus (Cramer et al., 2008; Kahle and Staley, 2008; Klein
et al., 1999; Ko et al., 2014; Price et al., 2005). As described in chapter 5, TQS reduces
neuroinflammatory pain by decreasing NF- κB activation and BDNF expression in the
hippocampus. However, the effects of TQS on NKCC1 and KCC2 expression and
NKCC1activation in the hippocampus are not known.
We hypothesized that TQS will decrease NKCC1 and KCC2 expression and
NKCC1 activation in the hippocampus during antiallodynic and antihyperalgesic effects
as reported earlier (Abbas and Rahman, 2016). Therefore, we have determined the effects
of TQS on NKCC1 and KCC2 expression and NKCC1 activation in the hippocampus. In
addition, we have examined the effects of TQS on phosphorylated cyclic adenosine
monophosphate response element binding protein (p-CREB) expression in the
hippocampus in mice.
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6.2. Methods
Animals
Male C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME,
USA). The mice were housed under standard laboratory conditions as mentioned before
(see chapter 2, section 2.2).
Drug treatment
The BU was purchased from Sigma-Aldrich (St. Louis, MO, USA) and was
dissolved in normal saline containing 0.25% NaOH. The BU (10 or 30 mg/kg) was
administered 1 h before the measurement of pain behavior (Cramer et al., 2008). The
source, method of reconstitution, and time of administration for other drugs used in this
study are mentioned previously (see chapter 2, section 2.2). Control animals were
administered an equal volume of vehicle. The doses for BU were chosen based on
previous report (Cramer et al., 2008).
Tactile allodynia
Tactile allodynia was measured as described before (see chapter 2, section 2.2).
Thermal hyperalgesia
Thermal hyperalgesia was quantified as mentioned earlier (see chapter 2, section
2.2).
RNA isolation and cDNA synthesis
Total RNA was isolated from hippocampal tissue as described previously (see
chapter 3, section 3.2).
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Quantitative real-time PCR
Quantitative real-time PCR was performed as mentioned previously (see chapter
3, section 3.2). Primers sequences were obtained from Integrated DNA Technologies
(Coralville, Iowa, USA) and are given in Table 4.
Table 4: Prime primer sequence for GAPDH, NKCC1, and KCC2
Primer sequence (5’-3’)

Gene
GAPDH

GTGGAGTCATACTGGAACATGTAG (forward)
AATGGTGAAGGTCGGTGTG (reverse)

NKCC1

GGTATCATTAACATTGCCAGTGG (forward)
CAGATCCTCAGTCAGCCATAC (reverse)

KCC2

AGCCTATGACGATGACCCA (forward)
CCACCTCTGCTGTCTACATC (reverse)

Western blot analysis
Western blot analysis was conducted as previously described in detail (see chapter
2, section 2.2). Briefly, equal amounts of protein (50 μg) were loaded onto 10% gels for
sodium dodecyl sulfate polyacrylamide gel electrophoresis. Membranes were then
blocked on a gyro-rocker with 5% nonfat dry milk in Tris-buffered saline/0.1% tween-20
for 50 min, and subsequently incubated overnight at 4°C with primary antibodies for pCREB (1:500, rabbit polyclonal, Santa Cruz Biotech, USA), or β-tubulin (E7-S, 1:5,000,
mouse monoclonal, University of Iowa, USA). After incubation, membranes were
incubated with appropriate horseradish peroxide-conjugated secondary antibodies. Bound
antibodies were detected with enhanced chemiluminescence prime reagent (Amersham,
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Buckinghamshire, UK), and protein quantification was performed using densitometric
analysis.
Immunofluorescence assay
Immunofluorescence assay was conducted as described previously (see chapter 3,
section 3.2) using primary antibody for phospho-NKCC1 (EMD Millipore, Billerica,
Massachusetts, USA).
Statistical analyses
For thermal hyperalgesia, Western blot analysis, immunofluorescence assay, and
quantitative real-time PCR, data were analyzed by one-way ANOVA followed by
Tukey’s post hoc test for multiple comparisons. For quantitative real-time PCR for MLA
and TQS/BU combination data for thermal hyperalgesia, Student’s t-test was used. For
tactile allodynia, Kruskil-Wallis test followed by Dunn’s post hoc test for multiple
comparisons or Mann-Whitney test for TQS/BU combination was applied using
GraphPad Prism 5.0 (GraphPad Inc., San Diego, CA, USA). The difference between
treatments was considered as significant at P < 0.05. All results are expressed as mean ±
S.E.M.
6.3. Results
Effects of BU on 50% paw withdrawal in von Fey filament test in LPS-induced
neuroinflammatory pain
The effects of BU on 50% paw withdrawal (tactile allodynia) during von Frey
filament test are shown in Figure 46. Kruskal-wallis test showed that BU significantly
affected 50% paw withdrawal threshold (P < 0.0001). Multiple comparisons of means
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revealed that LPS (1 mg/kg) significantly (P < 0.001) decreased 50% paw withdrawal
threshold compared to control showing the presence of pain hypersensitivity.
Furthermore, BU (30 mg/kg) significantly (P < 0.05) enhanced 50% paw withdrawal
threshold compared to LPS treatment group indicating antiallodynic effects of BU are
due to the blockade of NKCC1.

Figure 46: Lipopolysaccharide (LPS) significantly decreased 50% paw withdrawal
threshold (tactile allodynia) compared to control. Moreover, bumetanide (BU)
significantly increased 50% paw withdrawal threshold compared to LPS treated group.
Mice received BU (10 or 30 mg/kg, i.p.) 5 h after LPS administration. Control animals
received equal volume of vehicle. Paw withdrawal threshold was assessed using von Frey
filaments six h after LPS administration. Data are expressed as mean + S.E.M. (n = 58/group). *P < 0.05; **P < 0.001.
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Effects of BU on latency time in hot plate test in LPS-induced neuroinflammatory pain
The effects of BU on latency time (thermal hyperalgesia) in hot plate test are
shown in Figure 47. One way ANOVA showed that BU significantly altered latency time
in hot plate test (F3,19 = 8.794; P < 0.001). Multiple comparisons of means showed that
LPS (1 mg/kg) significantly (P < 0.001) reduced hot plate latency as compared to control
group indicating significant reduction in response to heat stimulus. Moreover, BU (30
mg/kg) significantly (P < 0.05) enhanced hot plate latency compared to LPS treatment
group indicating antihyperalgesic effects of BU are due to the blockade of NKCC1.

136
Figure 47: Lipopolysaccharide (LPS) significantly decreased latency time (thermal
hyperalgesia) on the hot plate. Moreover, bumetanide (BU) significantly increased
latency time on hot plate compared to LPS treated group. Mice received BU (10 or 30
mg/kg, i.p.) 5 h after LPS administration. Control animals received equal volume of
vehicle. Latency on hot plate was measured six h after LPS administration. Data are
expressed as mean + S.E.M. (n = 5-6/group). *P < 0.05; **P <0 .001.
Effects of co-administration of TQS and BU on 50% paw withdrawal threshold in von
Fey filament test in LPS-induced neuroinflammatory pain
The effects of co-administration of TQS and BU on 50% paw withdrawal threshold
(tactile allodynia) are displayed in Figure 48. Mann-Whitney test showed that coadministration of TQS and BU significantly (P < 0.01) decreased 50% paw withdrawal
threshold indicating reduction in the activation of NKCC1 during TQS-mediated
antiallodynic response.
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Figure 48: Lipopolysaccharide (LPS) significantly decreased 50% paw withdrawal
threshold (tactile allodynia) compared to control. Furthermore, TQS in combination with
bumetanide (BU) significantly increased 50% paw withdrawal threshold compared to
TQS treated group. Mice received BU (10 mg/kg, i.p.) 5 h after LPS administration. TQS
was given 30 minutes before LPS administration. Control animals received equal volume
of vehicle. Paw withdrawal threshold was assessed using von Frey filaments six h after
LPS administration. Data are expressed as mean + S.E.M. (n = 6-8/group). *P < 0.01,
**P < 0.0001.
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Effects of co-administration of TQS and BU on latency time in hot plate test in LPSinduced neuroinflammatory pain
The effects of co-administration of TQS and BU on latency time (thermal
hyperalgesia) are displayed in Figure 49. Student's t-test revealed that co-administration
of TQS and BU significantly (P < 0.01) elevated latency time in hot plate test indicating
antihyperalgesic effects of TQS are mediated through reduced NKCC1 activation.
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Figure 49: Lipopolysaccharide (LPS) significantly decreased latency time (thermal
hyperalgesia) on the hot plate. Moreover, TQS in combination with bumetanide (BU)
significantly increased latency time on hot plate compared to TQS treated group. Mice
received BU (10 mg/kg, i.p.) 5 h after LPS administration. TQS was given 0.5 h before
LPS administration. Control animals received equal volume of vehicle. Latency on hot
plate was measured six h after LPS administration. Data are expressed as mean + S.E.M.
(n = 6/group). *P < 0.01.
Effects of TQS on NKCC1 mRNA expression in the hippocampus
The effects of TQS on NKCC1 mRNA expression are displayed in Figure 50. One
way ANOVA showed that TQS did not significantly affect the expression of NKCC1
mRNA (F2,9 = 1.556; P > 0.05) in the hippocampus.
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Figure 50: TQS did not significantly affect the expression of NKCC1in the
hippocampus. Mice were administered TQS (4 mg/kg, i.p.) 0.5 h before LPS
administration. Control animals received equal volume of vehicle. Hippocampi were
collected 6 h after LPS administration. The NKCC1 mRNA expression was quantified
using quantitative real-time polymerase chain reaction. (n = 4/group). Data are expressed
as mean + S.E.M.
Effects of TQS on KCC2 mRNA expression in the hippocampus
The effects of TQS on KCC2 mRNA expression are displayed in Figure 51. One way
ANOVA showed that TQS significantly affected the expression of KCC2 mRNA (F2,9 =
13.17; P < 0.01). Multiple comparisons of means showed that LPS (1 mg/kg)
significantly (P < 0.01) reduced expression of KCC2 mRNA suggesting LPS-induced
neuroinflammatory pain might be due to decreased the expression of KCC2.
Furthermore, TQS (4 mg/kg) significantly (P < 0.05) increased the expression of KCC2
mRNA in LPS-induced neuroinflammatory pain supporting the hypothesis that TQS
reduced neuroinflammatory pain-like symptoms by increasing KCC2 expression in the
hippocampus.
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Figure 51: Lipopolysaccharide (LPS) significantly decreased K-Cl co-transporter 2
(KCC2) mRNA expression compared to control. Moreover, TQS significantly increased
the expression of KCC2 mRNA compared to LPS treated group. Mice were administered
TQS (4 mg/kg, i.p.) 0.5 h before LPS administration. Control animals received equal
volume of vehicle. Hippocampi were collected 6 h after LPS administration. The KCC2
mRNA expression was quantified using quantitative real-time polymerase chain reaction.
Data are expressed as mean + S.E.M. (n = 4/group). *P < 0.05; **P < 0.01.
Effects of MLA on TQS-induced increase in KCC2 mRNA expression in the hippocampus
The effects of MLA on TQS-induced increase in KCC2 mRNA expression are
displayed in Figure 52. Student's t-test indicated that MLA significantly (P < 0.05)
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reversed TQS-induced increase in KCC2 mRNA expression. This confirmed that TQSinduced increase in KCC2 mRNA is mediated through α7 nAChR.

Figure 52: Methyllycaconitine (MLA) significantly decreased K-Cl co-transporter2
(KCC2) mRNA expression compared to TQS treatment group. Mice were administered
TQS (4 mg /kg, i.p.) 0.5 h before LPS administration. The MLA (3 mg /kg, i.p.) was
given 10 min before TQS injection. Control animals received equal volume of vehicle.
Hippocampi were collected 6 h after LPS administration. The KCC2 mRNA expression
was quantified using quantitative real-time polymerase chain reaction.
expressed as mean + S.E.M. (n = 4/group). *P < 0.05; **P < 0.01.

Data are

143
Effects of TQS on p-NKCC1 expression in CA1 in hippocampus
The effects of TQS on p-NKCC1 expression in CA1 region of the hippocampus are
displayed in Figure 53. One way ANOVA showed that TQS significantly altered pNKCC1 expression in LPS-induced neuroinflammatory pain (F2,11 = 13.91; P < 0.01).
Multiple comparisons of means showed that LPS (1 mg/kg) significantly (P < 0.01)
elevated the expression of p-NKCC1. Furthermore, TQS (4 mg/kg) significantly (P <
0.01) decreased p-NKCC1 expression in CA1 region of hippocampus.
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Figure 53: Lipopolysaccharide (LPS) significantly increased phospho-Na-K-Cl
cotransporter1 (p-NKCC1) expression in CA1 region of hippocampus compared to
control. Moreover, TQS significantly reduced the expression of p-NKCC1 compared to
LPS treated group. Mice were administered TQS (4 mg/kg, i.p.) 0.5 h before LPS
administration. Control mice received equal volume of vehicle. Whole brain was
collected 6 h after LPS administration. The p-NKCC1 expression was quantified using
immunofluorescence assay. Data are expressed as mean + S.E.M. Representative images
show the immunofluorescence in CA1 in hippocampus. Magnification 20 X, Scale bar =
50 um. (n = 4-5/group). *P < 0.01.
Effects of TQS on p-NKCC1 expression in DG in hippocampus
The effects of TQS on p-NKCC1 expression in DG region of the hippocampus are
displayed in Figure 54. One way ANOVA showed that TQS significantly altered pNKCC1 expression in LPS-induced neuroinflammatory pain (F2,9 = 16.84; P < 0.001).
Multiple comparisons of means showed that LPS (1 mg/kg) significantly (P < 0.01)
elevated the expression of p-NKCC1. Furthermore, TQS (4 mg/kg) significantly (P <
0.001) decreased p-NKCC1 expression in DG region of hippocampus.
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Figure 54: Lipopolysaccharide (LPS) significantly increased phospho-Na-K-Cl
cotransporter1 (p-NKCC1) expression in dentate gyrus (DG) of hippocampus compared
to control. Moreover, TQS significantly reduced the expression of p-NKCC1 compared
to LPS treated group. Mice were administered TQS (4 mg/kg, i.p.) 0.5 h before LPS
administration. Control mice received equal volume of vehicle. Whole brain was
collected 6 h after LPS administration. The p-NKCC1 expression was quantified using
immunofluorescence assay. Data are expressed as mean + S.E.M. Representative images
show the immunofluorescence in DG in hippocampus. Magnification 20 X, Scale bar =
50 um. (n = 4/group) *P < 0.01; **P < 0.001.
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Effects of TQS on p-CREB expression in the hippocampus
The effects of TQS on p-CREB expression are displayed in Figure 55. One way
ANOVA showed that TQS did not significantly affect the expression of P-CREB (F3,12 =
0.1744; P = 0.9116) supporting the hypothesis that TQS did not affect neuronal α7
nAChR in the hippocampus.
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Figure 55: Lipopolysaccharide (LPS) did not significantly affect phosphorylated cyclic
adenosine monophosphate response element binding protein (p-CREB) expression
compared to control. Moreover, TQS did not reduce the expression of p-CREB compared
to LPS treated group. Mice were administered TQS (4 mg/kg, i.p.) 0.5 h before LPS
administration. Control animals received equal volume of vehicle. Hippocampi were
collected 6 h after LPS administration. The p-CREB expression was quantified using
quantitative real-time polymerase chain reaction. (n = 4/group). Data are expressed as
mean + S.E.M.
6.4. Discussion
The present study indicated that administration of TQS increased KCC2
expression and reduced NKCC1 activation in the hippocampus. TQS at same dose
decreased neuroinflammatory pain-like symptoms as reported earlier (Abbas and
Rahman, 2016). In support of this concept, co-administration of sub maximal dose of
both TQS and BU produced antiallodynic and antihyperalgesic effects. This validates
TQS-mediated antiallodynic and antihyperalgesic effects are due to decreased NKCC1
activation in the hippocampus. Furthermore, TQS-induced increase in KCC2 mRNA
expression was reversed by MLA confirming the involvement of α7 nAChR in TQS
effects. TQS also decreased the immunoreactivity of phospho-NKCC1, the active form of
NKCC1, in CA1 and DG regions of hippocampus indicating TQS decreases
neuroinflammatory pain through reducing NKCC1 activation in the hippocampus. Taken
together, these data strongly suggest that increased expression of KCC2 and reduced
activation of NKCC1 is critically involved in the mediation of TQS-induced antiallodynic
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and antihyperalgesic effects involving α7 nAChR positive allosteric modulation in our
mouse model for neuroinflammatory pain.
Our data are consistent with this view that neuronal NKCC1 and KCC2 are key
elements in LPS-induced neuroinflammatory pain model. Dysregulation of NKCC1 and
KCC2 were shown to be involved in the pathophysiology of neuroinflammatory pain. For
example, acute inflammatory pain was reported to be due to increased expression of
NKCC1 and reduced KCC2 expression in CNS (Galan and Cervero, 2005; Nomura et al.,
2006). The NKCC1 knockout mice were shown to exhibit reduced neuroinflammatory
pain-like symptoms (Sung et al., 2000). Our observations, of coincident effects of TQS
on the pain behavior and decreased NKCC1 activation and increased KCC2 expression
provide support to above findings. This validated a link between decreased NKCC1
activation and increased KKC2 expression, and reduced pain hypersensitivity in LPSinduced neuroinflammatory pain model in mice. Together, these findings suggest that
NKCC1 and KCC2 might be required for inflammatory pain in animal models. For
example, inflammation was shown to increase NKCC1 activation and reduce KCC2
activity resulting in increased painful response (Nomura et al., 2006; Payne et al., 2003;
Price et al., 2005; Valencia-de Ita et al., 2006). Furthermore, phosphorylation of NKCC1
and decreased KCC2 expression result in increased pain behavior (Galan and Cervero,
2005; Nomura et al., 2006) . Thus, activated NKCC1, was found to induce
neuroinflammatory pain-like symptoms in animal models (Lee et al., 2014).
Our findings showed that co-administration of TQS with BU had synergistic
effects in decreasing neuroinflammatory pain-like symptoms which indicates
involvement of NKCC1 in antiallodynic and antihyperalgesic effects. Moreover, the
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pretreatment of MLA, an α7 nAChR antagonist, reversed TQS-induced increase in KCC2
mRNA expression in the hippocampus validating the involvement of α7 nAChRs. To the
best of our knowledge, this is the first report which shows that α7 nAChR positive
allosteric modulation in the hippocampus causes increased KCC2 expression and reduced
NKCC1 activation in neuroinflammatory pain. We propose that NKCC1 activation need
to be inhibited and KCC2 expression might be increased for the blockade of LPS-induced
neuroinflammatory pain.
Our results indicated that LPS increased the phosphorylation of NKCC1
(activated NKCC1) in DG and CA1 regions, hippocampal regions involved in pain
processing and perception, in LPS-induced painful conditions. TQS, however, resulted in
marked decrease in NKCC1 activation in these both regions indicating that TQS reduces
painful behavior via decreased activity in DG and CA1. However, further studies are
warranted involving direct microinjection of LPS and/or TQS in the hippocampus.
As reported earlier α7 nAChRs are found both on neuronal and non-neuronal cells,
including microglial cells (Pocock and Kettenmann, 2007; Taly et al., 2009). Signaling
through microglial α7 nAChRs is different from those neuronal α7 nAChRs (Suzuki et
al., 2006). For example, a previous study has shown that signaling through activated
neuronal α7 nAChR involves increased expression of p-CREB (Dajas-Bailador and
Wonnacott, 2004). However, microglial α7 nAChR-mediated signaling involves
decreased expression of NF-κB (Egea et al., 2015; Loram et al., 2010). Our results
showed there was no change in the expression of p-CREB in the hippocampus excluding
the involvement of neuronal α7 nAChR. Furthermore, as reported in chapter 3, TQS
pretreatment decreased the activation of NF-κB indicative of microglial α7 nAChR
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involvement. Moreover, changes in microglial morphology, reduced expression of Iba-1
and CD11b mRNA after TQS administration in the hippocampus are suggestive of
involvement of microglia in LPS-induced neuroinflammatory pain. We, therefore,
propose that TQS-mediated antiallodynic and antihyperalgesic effects are due to
microglial α7 nAChR activation and associated pathway.
In conclusion, our study determined the effects of reduced KCC2 expression and
active NKCC1 in pain facilitation in the hippocampus in neuroinflammatory pain.
Overall, we propose that inhibition of NKCC1 activation and enhancement of KCC2
expression are critical and novel therapeutic approach for the clinical utility of
neuroinflammatory pain.
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Chapter 7: General Discussion

The findings presented in this dissertation determined the effects of microglial α7
nAChR positive allosteric modulation-mediated signaling in the hippocampus in LPSinduced neuroinflammatory pain associated with microglial activation using widely
established mouse models.
In chapter 2, we found that TQS significantly decreased tactile allodynia and
thermal hyperalgesia in LPS-induced neuroinflammatory pain. Pretreatment with MLA
reversed TQS-induced antiallodynic and antihyperalegesic effects validating the
involvement of α7 nAChR in the mediation of TQS effects in reduced pain behavior. Our
results are consistent with previous findings (Loram et al., 2010) and support the notion
that activating α7 nAChR reduces pain hypersensitivity in our mouse models of
neuroinflammatory pain. Furthermore, we demonstrated that TQS significantly reduced
the expression of Iba-1 in the hippocampus indicating reduced microglial activation.
Previous study also showed that decreasing microglial activation reduces
neuroinflammatory pain involving reduced Iba-1 expression in spinal cord (Yoon et al.,
2012). Microglial activation has been found to be associated with increased NF-κB
activation (Loram et al., 2010). Our results are novel regarding the role of microglial cells
in hippocampus in neuroinflammatory pain as hippocampus is a less studied supraspinal
area with regard to pain perception and processing. Furthermore, hippocampus is
connected to other brain areas that play critical role in modulating pain behavior. The
microglial inhibitors such as propentofylline decreases pain hypersensitivity (Sweitzer et
al., 2001). Conversely, fractalkine, the microglial activator, produces behavioral signs of
neuroinflammatory pain, including allodynia, and hyperalgesia (Milligan et al., 2004).
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TQS alone did not produce antiallodynic and antihyperalgesic effects, indicating TQS
reduces tactile allodynia and thermal hyperalgesia asoociated with microglial activation.
Overall, our results indicate the critical role of microglial α7 nAChR in LPS-induced
neuroinflammatory pain and provide strong evidence that positive allosteric modulation
is a novel approach to reduce neuroinflammatory pain associated with microglial
activation in the hippocampus. Therefore, α7 nAChR PAM can be developed as potential
drug candidate for neuroinflammatory pain.
In order to examine the effects of microglial α7 nAChR positive allosteric

modulation-mediated signaling, we determined the effects of TQS on NF-κB activation as
described in chapter 3. Our results showed that TQS reduced the expression of IκB, a
downstream mediator which decreases as NF-κB becomes inactivated, indicating NF-κB
inactivation. TQS also reduced microglial activation by decreasing the expression of CD11b
mRNA, a microglial activation marker, in the hippocampus. Pretreatment with sub maximal
dose of TQS and TEL reduced LPS-induced tactile allodynia and thermal hyperalgesia. In
addition to reduced neuroinflammatory pain-like symptoms, co-administration of TQS with
TEL decreased LPS-induced increase in NF-κB and microglial activation by decreasing IκB
mRNA and CD11b mRNA expression. This validated our hypothesis that TQS reduces

neuroinflammatory pain by decreasing NF-κB activation associated with microglial
activation. Our results are in line with previous studies and indicate that increased

neuroinflammatory pain-like symptoms are associated with NF-κB activation in the CNS
(Loram et al., 2010). TQS prevented LPS-induced increased immunoreactivity of p-NF-κB

p65 in CA1 and DG of the hippocampus indicating microglial α7 nAChRs play important
role in reducing neuroinflammatory pain mediated by microglial NF-κB activation. The
inactivation of NF-κB might be due to inhibition of IκB degradation associated with
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increased intracellular Ca+. This results in reduced translocatuon of active NF-κB within

nucleus and decreases gene expression for pain mediators, including TNF, and BDNF.
Previous studies have indicated that NF-κB is novel target for pain management. For
example, systemic administration of NF-κB inhibitor decreases neuroinflammatory painlike symptoms (Tegeder et al., 2004). Also, intrathecal administration of ammonium
pyrrolidinedithiocarbamate and SN50, NF-κB inhibitors, modulate neuroinflammatory
pain-like symptoms in animal models (Ledeboer et al., 2005). Taken together, our
findings in chapter 3 indicate that reducing NF-κB within hippocampus is a novel strategy
for reducing neuroinflammatory pain involving microglial α7 nAChR positive allosteric
modulation. Due to potential ability to reduce NF-κB activation, the α7 nAChR PAM might
be de novel therapeutic agent for neuroinflammatory pain.

As indicated earlier, NF-κB is critically involved in the expression of TNF,
therefore, in chapter 4, we examined the effects of TQS on TNF expression in the
hippocampus. Our findings indicated that TQS significantly reduced TNF expression in
the hippocampus. TQS (1 mg/kg) did not affect TNF mRNA expression but decreased
TNF level in the hippocampus in LPS-induced neuroinflammatory pain. This could be
due to involvement of other downstream signaling pathway involved in post
transcriptional modification of TNF that needs to be explored. Furthermore, TQS also
increased the level of NE in the hippocampus. Our results support that a relationship
exists between TNF and NE level in the hippocampus and showed that decreasing TNF
resulted in increased NE in the hippocampus. Previous studies also support the same
concept involving inverse relationship between TNF and NE in the hippocampus (Covey
et al., 2000; Ignatowski et al., 1999). According to this hypothesis, increasing TNF in the
hippocampus results in the alteration of α2 adrenergic receptor coupling to Gi/Gs-
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proteins (Sud et al., 2008). For example increased TNF increases Gi-protein coupling
with α2 adrenergic receptor compared to Gs-protein. This results in reduced NE release
in the hippocampus and increased pain sensitivity. However, decreasing TNF increases
Gs-proteins coupling with α2 adrenergic receptor compared to Gi-proteins thus
facilitating NE release in the hippocampus as seen as with TQS pretreatment after LPS
administration. The MLA reversed TQS-induced decrease in TNF mRNA indicating the
involvement of α7 nAChR in the expression of TNF. Pretreatment of IDA reversed TQSinduced antiallodynic and antihyperalgesic effects. The IDA also reduced TQS-mediated
increase in NE level. This validated the involvement of α2 adrenergic recptor in the
mediation TQS effects on tactile allodynia and thermal hyperalgesia and NE release.
Furthermore, TQS reduced the immunoreactivity of TNF in DG and CA1 regions of the
hippocampus. The findings from chapter 3 indicate that TNF and NE in the hippocampus
are potential drug targets and decreasing TNF and increasing NE might be novel
approach for the treatment of neuroinflammatory pain involving α7 nAChR positive
allosteric modulation. Due to reduction in TNF expression and increased NE level, α7
nAChR PAM might be potential drug candidate for neuroinflammatory pain.
We determined the effects of TQS on BDNF expression in the hippocampus as

shown in chapter 5. Our results indicated that LPS significantly increased the expression
of microglial BDNF indicating painful behavior is directly associated with enhanced
BDNF level in the hippocampus. In line with our results, previous study showed that
increased expression of microglial BDNF plays a critical in the mediation of Painful
behavior (Coull et al., 2005). Our results showed that acute treatment with TQS
decreased the expression of BDNF in the hippocampus. The TQS (1 mg/kg) reduced
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BDNF mRNA expression while it did not decrease BDNF indicating TQS (1 mg/kg)
might not be bio-available enough to affect post transcriptional modification of BDNF in
the hippocampus. The administration of sub maximal dose of TQS with ANA-12
decreased tactile allodynia and thermal hyperalgesia. These results, therefore, indicate
that TQS reduces neuroinflammatory pain by decreasing BDNF expression in the
hippocampus. Moreover, TQS reduced the expression of BDNF in CA1 and DG regions
of the hippocampus. Previous studies showed that BDNF is critically involved in the
expression of NKCC1 and KCC2 in neurons. The up regulation and increased activation
of NKCC1 while down regulation of KCC2 in neurons cause neuroinflammatory pain
development involving BDNF-TrkB pathway. These results, therefore, indicate that
reduced expression of BDNF and BDNF-mediated signaling is critically involved in
antiallodynic and antihyperalgesic effects of TQS. Since TQS decreases microglial
BDNF expression, therefore, α7 nAChR PAM might be novel therapeutic agent for
neuroinflammatory pain.
As reported in earlier, BDNF is involved in the expression of NKCC1 and KCC2
in neuroinflammatory pain, therefore, in chapter 6, we determined the effects of TQS on
the regulation of NKCC1 and KCC2. Our findings showed that TQS reduced NKCC1
activation and increased KCC2 expression resulting in reduced neuroinflammatory painlike symptoms. Moreover, the sub maximal dose of both TQS and BU reduced LPSinduced tactile allodynia and thermal hyperalgesia. This validated the involvement of
NKCC1 in the mediation antiallodynic and antihyperalgesic effects of TQS. Our findings
in this chapter indicate that TQS reduces neuroinflammatory pain by decreasing BDNFinduced neuronal hypersensitization involving BDNF-TrkB pathway. Previous studies

156
have reported that the activation of NKCC1 and decreased expression of KCC2 causes
increased intracellular movement of Cl-1 within neurons. So, intracellular concentration
of Cl- builds up in the neurons. The binding of GABA at its receptor results in outward
movement of Cl-1. This results in depolarization and increased pain sensitivity as seen
after LPS administration. However, further studies are warranted involving the
measurement of Cl-1 within neurons. Our findings indicate that reduced expression of
KCC2 and increased activation of NKCC1 play a critical role in pain hypersensitivity in
neuroinflammation. Therefore, α7 nAChR PAM might be potential drug candidate for
neuroinflammatory pain.
Overall, our findings revealed TQS decreased microglial TNF and BDNF
expression and associated signaling in neuroinflammatory pain involving α7 nAChR and
microglial activation in the hippocampus in mice. Therefore, TQS triggers microglial α7
nAChR positive allosteric modulation-mediated signaling pathway resulting in reduced
painful symptoms in LPS-induced neuroinflammatory pain in mice as depicted in our
proposed mechanism in Figure 56. Therefore, targeting α7 nAChR positive allosteric
modulation on the microglia in the hippocampus is a novel strategy for the treatment of
neuroinflammatory pain.
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Figure 56: Schematic for proposed signaling pathways involved in α7 nicotinic
acetylcholine receptor (nAChR) positive allosteric modulation-mediated antiallodynic
and antihyperalgesic effects in neuroinflammatory pain. The 3a,4,5,9b-tetrahydro-4-(1naphthalenyl)-3H-cyclopentan[c]quinoline-8-sulfonamide (TQS) binds at allosteric site
of α7 nAChR and acetylcholine (ACh) binds at orthosteric site on microglia in dentate
gyrus and CA1 regions of the hippocampus. This causes decrease in nuclear factorkappa-B (NF-κB), a transcription factor, activation through reduced microglial activation.
This results in decrease in the induction and release of proinflammatory cytokines-tumor
necrosis factor (TNF) and brain-derived neurotrophic factor (BDNF). Decreased TNF in
the hippocampus disturbs the balance between Gαi-protein and Gαs protein and favors
one functional form (coupled to Gαs) over the other (coupled to Gαi) at presynaptic α2adrenergic autoreceptor. This increases norepinephrine (NE) release from noradrenergic
neurons and decreases pain sensation. Moreover, decreased BDNF also reduces neuronal
sodium-potassium-chloride co-transporter 1 (NKCC1) activation. Reduced BDNF also
increases the expression of potassium-chloride co-transporter 2 (KCC2). This inhibits
action potential generation and decreases pain sensitivity in neuroinflammatory pain.
Modified and adopted from Covey et al. (2000) Brain Res 859:113-122; Gomes et al.
(2013) J Neuroinflammation 10:16; Kahle et al. (2008) Nat Clin Pract Neurol 4:490-503;
Loram et al. (2010) Brain Behav Immun 24:959-967; Miwa et al. (1997) J Neurosci Res
50:1023-1029; Price et al. (2005) Curr Top Med Chem 5:547-555 and Sud et al. (2008)
Eur J Pharmacol 588:217-231.
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Summary and conclusions
The main findings of this dissertation are given below:
Microglial α7 nAChR-mediated effects play a critical role in the reduction of

i.

neuroinflammatory pain involving reduced microglial activation in the
hippocampus (chapter 2).
Microglial α7 nAChR-mediated signaling decreases the activation of NF-κB in

ii.

neuroinflammatory pain in the hippocampus (chapter 3).
iii.

Microglial α7 nAChR-mediated signaling reduces the expression of TNF and
increases NE level in neuroinflammatory pain in the hippocampus (chapter 4).
Microglial α7 nAChR-mediated signaling modulates the expression of BDNF in

iv.

neuroinflammatory pain in the hippocampus (chapter 5).
Microglial α7 nAChR-mediated signaling modulates the activation of NKCC1

v.

and increases the expression KCC2 in hippocampal neurons in
neuroinflammatory pain (chapter 6).
In conclusion, the current dissertation provided a novel discovery that microglial α7
nAChR positive allosteric modulation-mediated signaling regulates behavioral, cellular,
biochemical, and molecular mechanisms underlying neuroinflammatory pain in the
hippocampus in mice.
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Future directions
The findings provided in this dissertation provide strong evidence for the critical role
of microglial α7 nAChR positive allosteric modulation and associated signaling in
neuroinflammatory pain. This gives rise to other future directions that include
i.

We have examined the role of microglial cells and associated mechanisms in
neuroinflammatory pain in the hippocampus in mice. Moreover, astrocytes play
critical in the maintenance of neuroinflammatory pain, therefore futures studies
are required to investigate the role of astrocytes in the hippocampus in
neuroinflammatory pain.

ii.

Our results have shown that proinflammatory cytokine, TNF plays a critical role
in the development of neuroinflammatory pain. Previous studies indicate that
other proinflammatory cytokines, including IL-1β, and IL6 are also involved in
neuroinflammatory pain. Therefore, additional studies are needed to investigate
the effects of IL-1β, and IL6 in the hippocampus in neuroinflammatory pain.

iii.

We focused the involvement of hippocampus in LPS-induced neuroinflammatory
pain. Additional studies are warranted to examine the role of other limbic regions
including amagdyla, and anterior cingulated cortex in neuroinflammatory pain.
Furthermore, the role of prefrontal cortex should be determined in
neuroinflammatory pain.

iv.

We have examined the effects of TQS in the hippocampus in neuroinflammatory
pain in regular mice. Future studies involving the use of microglial α7 nAChR
transgenic and knockout mice are required in order to further confirm the
involvement of microglial α7 nAChR in neuroinflammatory pain.
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